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Executive Summary 
Despite consistent efforts of the government and national stakeholders, every year in Bangladesh over 5,000 
mothers and thousands of children die. Most of these deaths are preventable and could be treated by 
increased access to quality services including existing medicines and other health commodities. The United 
Nation’s Commission on Life-Saving Commodities for Women and Children suggests that an important cause 
of these deaths is lack of access and appropriate use of 13 life-saving commodities. 
This document describes an effort by Population Council to assess the country’s policies, guidelines, and 
availability for these 13 life-saving commodities as well as engaging with key stakeholders to implement the 
UN Commission’s recommendations in conjunction with this assessment’s findings. This assessment validated 
the availability of the 13 commodities in three districts at district, sub-district, and community levels, and 
within drug stores, in in 15 government facilities and 27 private drug stores in August and September 2013. 
Key stakeholders (including Ministry of Family Health and Welfare and government officials, members of 
professional associations, and non-governmental representatives) were consulted. A national workshop 
stimulated discussion, identified national priorities and information gaps, and identified areas requiring policy 
review. This stakeholder engagement helped identify opportunities for their organizations’ contributions to 
implementing the UN Commission recommendations. 
FINDINGS 
Regulatory issues 
The assessment determined that Bangladesh has well-developed policies to regulate production, distribution, 
sale, and use of all drugs as well as ensuring they are of good quality, efficacious, and safe. It is also revealed 
that all drugs, medicines, and other mechanical substances in final dosage forms (those manufactured, 
imported, distributed, marketed, or consumed in the country) must be registered with the regulatory authority—
the Directorate General of Drug Administration. The the registration must specify dosage form and strength, 
according to the country’s Drug Control Committee (a committee of the Directorate General of Drug 
Administration). The Directorate General of Drug Administration’s capacity seems to be logistically limited and 
lacks skilled manpower, while other regulatory factors including pharmaceutical companies’ individual 
operating procedures, quality control, and quality assurance programs complicate regulatory issues.  
Registration and commodity availability  
The assessment found that many policymakers and program managers are not aware of the UN Commission 
report nor its recommendations. Stakeholders who were aware were generally from international and UN 
organizations and involved in actual implementation of the Commission’s recommendations. 
With the exception of the female condom, however, each of the 13 life-saving commodities is registered and 
available in Bangladesh. Not all of maternal and neonatal commodities are registered in the dosage forms 
recommended by the World Health Organization for their specified indications, nor do service delivery 
guidelines provide indications for their use.  
Availability and shortage need to be addressed. Oxytocin and Misoprostol were not available in two out of three 
district hospitals visited but were available in all Mother and Child Welfare Centers. Similarly, Misoprostol was 
not available in any Union Health and Family Welfare Centers or Community Clinics visited.  
Although Oxytocin is available and used for induction of labor and preventing postpartum hemorrhage in most 
district and sub-district facilities (although not in community facilities), consistent lack of cold chain storage 
necessary for the drug’s integrity remains a significant challenge. Many government facilities and most private 
drug stores lack functioning refrigerators. Often Oxytocin is stored on an open shelf, rendering it ineffective.  
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Misoprostol is registered in Bangladesh and, in recent years, was introduced and scaled up for postpartum 
hemorrhage prevention and management at the community level. Service Delivery Guidelines are available for 
community use. Thus far, 19 out of 64 districts have the Guidelines. Discussions are ongoing to bundle 
Misoprostol with safe delivery kits. 
Magnesium sulphate is registered for prevention and treatment of severe pre-eclampsia and eclampsia, but it 
was not available in one out of two Mother and Child Welfare Centers and two out of five Upazila Health 
Complexes visited. Service delivery guidelines are available for community service providers. Community 
service providers tend to prefer single dose solutions for intramuscular injection in a pilot study underway in 
two sub-districts and upazilas, rather than other dosages or formulations. Population Council is currently 
conducting a study to determine whether it is feasible and acceptable for community service providers to 
administer an intramuscular loading dose of magnesium sulfate before referral.  
Several injectable antibiotics, including those recommended by the United Nations Commission, including 
amoxicillin for treatment of pneumonia, are registered and available in various dosage forms for treating 
neonatal sepsis and other infectious conditions. Injectable antibiotics were not available in one out of three 
District Hospitals, no Mother and Child Welfare Centers, nor two out of five Upazila Health Complexes.  
Chlorhexidine is registered and available in various dosage forms but not in the concentration necessary for 
neonatal cord care. Chlorhexidine 7.1% is not included in the country’s Essential Drug List or Dietary and Drug 
Supply Kits, and no Service Delivery Guidelines are available. Although the antenatal corticosteroids 
dexamethasone and betamethasone are registered and available in the country in various dosage forms, the 
available dosage forms are not suitable for pre-term respiratory distress syndrome and are not included in the 
Essential Drug List, and no Service Delivery Guidelines are available.  
Encouragingly, the National Core Committeef for Neonatal Health of the Directorate General of Health Services 
and the Directorate General of Family Planning’s National Technical Committee have approved piloting and 
scale up in one district of the required dose of dexamethasone for pre-term respiratory distress syndrome and 
Chlorhexidine 7.1% for neonatal cord care. Service Delivery Guidelines are being prepared.  
Oral rehydration salts and zinc are widely available as over-the-counter products and are used for diarrhea. 
Both are included in the Essential Drug List, and Service Delivery Guidelines are available.  
Resuscitation devices for newborn asphyxia have been distributed to 19 districts. The devices were available in 
two out of three District Hospitals, one out of two Mother and Child Welfare Centers, three out of five Upazila 
Health Complexes, two out of four Union Health and Family Welfare Centres, and no Community Clinics visited. 
Resuscitation devices for newborn asphyxia were not found in any private drug stores. 
Two types of contraceptive implants are registered. A single rod implant (Implanon) is registered and used in 
the government program, while a two rod implant, Jadelle (as I-plant), is registered and marketed in the private 
sector through Social Marketing Company. These are included in the country’s approved contraceptive 
methods and Service Delivery Guidelines are widely available. Although there is no domestic manufacturing of 
implants, there were no supply shortages of implants in the facilities visited. 
Emergency Contraceptive Pills are registered and have been used in Bangladesh for the last decade as an 
over-the-counter product, free of cost in the government program. Supplies are obtained from four domestic 
pharmaceutical companies, as well as imports, yet actual supplies in facilities are inconsistent. Although 
Emergency Contraceptive Pills were available in private drug stores, the drug was unavailable in government 
facilities.  
The female condom is not registered in Bangladesh, as policymakers and program managers consider it 
unsuitable for the local context. 
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Challenges Identified  
• Shortages of all essential drugs and commodities in public health facilities; 
• Inappropriate storage of oxytocin (and subsequent use of an ineffective drug during crucial medical events) 
is widespread; 
• Unavailability of antenatal corticosteroids in correct dosage forms (6 mg injection) for pre-term respiratory 
distress syndrome; unavailability of Chlorhexidine in the correct concentration (7.1%) for newborn cord care; 
provider use of inappropriate concentration; and lack of related Service Delivery Guidelines; 
• Unavailability of magnesium sulfate in appropriate dose forms; manufacture of a single loading dose for 
severe pre-eclampsia and eclampsia is needed, but pharmaceutical companies lack interest; 
• Lack of advocacy with pharmaceutical companies for manufacturing less profitable but essential drugs in 
appropriate dosage forms; 
• Lack of awareness of Emergency Contraceptive Pills due to lack of educational efforts; 
• Lack of knowledge and low use of zinc sulphate for neonatal diarrhea; 
• Absence of a Directorate General of Family Planning forum for advocating for mothers and ensuring access 
to and use of essential maternal health drugs and commodities. 
Opportunities Identified 
• All 13 life-saving drugs and commodities are registered (except female condom) in the country in different 
dosage forms, which means that additional, altered dosage forms is feasible. 
• The Directorate General of Drug Administration is very much in favor of ensuring the availability, quality, and 
affordability of essential maternal and neonatal health drugs and commodities. The Directorate requested 
an application for the approval of essential drugs in required dose forms. The Directorate General of Family 
Planning was requested to form an advocacy forum to ensure availability of maternal health drug and 
commodities, and Systems for Improved Access to Pharmaceuticals and Services supported a Forecasting 
Working Group in the Directorate. The Directorate General of Health Services has a Supply Chain 
Coordination Forum that coordinates with the United Nations, World Bank, the Joint United Nations 
Programme on HIV/AIDS, the Ministry of Family Health and Welfare, and other stakeholders. 
• Chlorhexidine has already been approved by the Directorate General of Drug Administration in the 
appropriate concentration, and the National Core Committee for Neonatal Health of the Directorate General 
of Health Services and the Directorate General of Family Planning’s National Technical Committee have 
approved its use in the vertical program. Social Marketing Company has reportedly begun manufacturing the 
drug, and Save the Children is piloting product use in one district. 
• The National Core Committee for Neonatal Health of the Directorate General of Health Services and the 
Directorate General of Family Planning’s National Technical Committee have approved the introduction and 
scale up of dexamethasone sodium sulphate 6 mg intramuscular injection for pre-term respiratory distress 
syndrome for both facilities and use within communities.  
• The Directorate General of Drug Administration has issued a letter for the appropriate storage of oxytocin in 
all public health facilities. The Directorates General of Health Services and Family Planning have also issued 
guidance to all facilities. 
• Systems for Improved Access to Pharmaceuticals and Services and other stakeholders are facilitating both 
the Directorate General of Health Services’ and the Directorate General of Family Planning’s quantification of 
maternal and neonatal commodities needed for the facility level. The Directorate General of Family Planning 
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has a logistics managment and information system for tracking the 13 recommended commodities, and they 
have also proposed including Chlorhexidine and misoprostol in standard infant delivery kits. 
• Participating respondents are concerned about the unavailability and inappropriate dosage forms of 
maternal and neonatal commodities, which suggests a wide basis of support for improved commodity 
availability. 
• Participating respondents are concerned about the use of low dose misoprostol for postpartum hemorrhage 
prevention and treatment. 
• Social Marketing Company and EngenderHealth’s Mayer Hashi program have initiated training to insert and 
remove implants through private providers. 
Recommendations 
For Maternal Health  
• Misoprostol should be bundled with birthing delivery kits. 
• Manufacture of a single loading dose of the magnesium sulfate solution should be consistently advocated 
for with pharmaceutical companies. 
• Stakeholders suggest an assessment of the effectiveness of 400 mcg versus 600 mcg misoprostol for 
preventing postpartum hemorrhage among Bangladeshi women. 
• Essential drugs and commodities for mothers should be made available at Union Health and Family Welfare 
Centres where normal vaginal deliveries are planned and conducted. 
For Neonatal Health 
• Chlorhexidine should be bundled with birthing delivery kits. 
• Resuscitation devices should be available in all districts, particularly in all facilities where deliveries are 
conducted. 
• Advocacy should be conducted with pharmaceutical companies for manufacture of a single dose of 
gentamycin injection and 7.1% Chlorhexidine. 
• Essential drugs and commodities for neonates should be made available in Union Health and Family Welfare 
Centres, where normal vaginal deliveries are planned and conducted. 
• Single doses of injectable antibiotics should be manufactured and promoted for neonatal sepsis. 
• Educational efforts should be strengthened for increasing awareness of zinc use in diarrheal diseases. 
For Family Planning Commodities 
• The Directorate General of Family Planning should increase public awareness how to avoid unplanned 
pregnancies and ensure availability of Emergency Contraception, including provision for field workers. 
General recommendations 
• A forum at the Directorate General of Family Planning should be formed to advocate for ensuring access to 
and use of maternal and newborn drugs and commodities. 
• Further initiatives are necessary for ensuring drug quality, dosage appropriateness, and reliable availability in 
both the private and public sectors. 
• The Directorates General of Drug Administration, Family Planning, and Health Services should be regularly 
updated by active stakeholders on global updates in maternal and neonatal health and other public health 
issues. 
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Background  
The United Nations (UN) Secretary General’s Global Strategy for Women’s and Children’s Health 2010 report 
highlighted the lack of access to life-saving commodities resulting in preventable deaths of women and 
children. The Strategy called on the global community to work together to save 16 million lives by 2015 
through increasing access to and appropriate use of essential medicines, medical devices and health supplies 
during pregnancy, childbirth, the postnatal period, and childhood. 
The UN secretary General convened the UN Commission on Life-Saving Commodities for Women and Children 
(the Commission), which is a part of the Every Woman, Every Child movement, with the overall goal of 
increasing access to life-saving commodities in 50 of the world’s poorest countries. The Commission identified 
and endorsed an initial list of 13 overlooked life-saving commodities that, if more widely accessed and properly 
used, could save the lives of more than six million women, newborns, and children, including prevention of 1.8 
million child deaths annually and 230,000 maternal deaths, through increased access to family planning (FP) 
around the world. The 13 commodities identified include oxytocin and misoprostol for postpartum hemorrhage 
(PPH), Magnesium sulphate (MgSO4) for severe pre-eclampsia and eclampsia, injectable antibiotics for 
newborn sepsis, Antenatal corticosteroids (ANCS) for pre-term respiratory distress syndrome, chlorhexidine for 
newborn cord care, resuscitation devices for newborn asphyxia, amoxicillin for pneumonia, oral rehydration 
salts (ORS) and zinc for diarrhea; and female condoms, contraceptive implants, and emergency ontraceptive 
pills (ECPs) for contraception.  
The Commission also identified key interrelated barriers that prevent access to and use of the 13 
commodities, which severely under-resourced regulatory agencies in low-income countries, leading to delayed 
registration of commodities; lack of oversight of product quality and general inefficiencies; market failures, 
where return on investment is too low for encouraging manufacturers to enter the market or produce sufficient 
quantities; and user supply and demand challenges such as limited demand for the product by end users, local 
delivery problems, and incorrect prescription and use. To address these challenges and deliver on the promise 
of saving the lives of millions of women, newborns, and children, the Commission recommended ten actions to 
be achieved within definite preriods of time. These actions focus on the need for improving global and local 
markets for life-saving commodities, innovative financing, quality strengthening and regulatory efficiency, 
improved national commodity delivery, and better integration of private sector and consumer needs.  
In Bangladesh, 12 of the 13 commodities are registered (except female condoms), but the extent to which 
these commodities are available at point of presacription and use, their doses and forms, policies for use, 
client access, and awareness are not widely, particularly at the district level. Furthermore, little is known about 
health workers’ knowledge and technical competencies. Bangladesh’s Ministry of Health and Family Welfare 
(MoHFW) comprises two divisions: the Directorate General of Health Services (DGHS), responsible for ensuring 
availability of maternal child health drugs, supplements, and devices; and the Directorate General of Family 
Planning (DGFP), which is responsible for ensuring contraceptive availability. DGFP is also responsible for 
ensuring availability of maternal child health drugs, supplements, and devices, in addition to contraceptives, at 
health facilities. The Directorate General of Drug Administration (DGDA) under MoHFW is the country’s Drug 
Regulatory Authority. 
Globally, efforts are underway to implement the UN Commission recommendations on Life-Saving Commodities 
for Women and Children. In an effort to contribute to the Government of Bangladesh’s implementation plan for 
these recommendations, Population Council, with support from the Hewlett Foundation, assessed the 
availability of the 13 life-saving commodities to provide empirical information for decision making within the 
country’s health sector. 
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Objective  
This assessment’s primary objective was to examine the policies, guidelines, and availability for the 13 
identified life-saving commodities in Bangladesh as well as engaging with policymakers and program managers 
in implementing the UN Commission recommendations in light of the assessment’s findings. This 
assessment’s findings are expected to be used as to stimulate discussion, identify national priorities and 
information gaps, influence policy formulation, and increase access to the commodities and assist 
international advocates for global advocacy. The specific objectives of this exercise are to: 
 Engage with national leaders on determining national priorities and information gaps about the 13 maternal 
and neonatal health products; 
 Examine policies and guidelines of the 13 life-saving commodities; 
 Explore procurement mechanisms of the 13 life-saving commodities/supplies; 
 Explore manufacturing capacity, availability of quality assurance guidelines and policies, product packaging 
policies, distribution mechanisms, cost to end users and financing;  
 Examine access to and availability of the 13 life-saving commodities at public sector facilities at district, sub-
district, and community levels, as well as at private drug stores; 
 Assess stakeholders’ and professional associations’ interest and participation in ensuring commodity 
supplies; and 
 Stimulate discussion among decision makers and help identify policy options for increasing commodity 
access and availability. 
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Methodology 
This Maternal Health Commodity Landscaping Exercise comprised two activities: assessing and providing a 
comprehensive description of maternal and neonatal health (MNH) commodity issues, from policy formulation 
to point of care; and engaging stakeholders for implementing the UN Commission recommendations. The 
study’s methodology included a document review of the policies, service guidelines, and availability and use of 
the 13 life-saving commodities as well as validating the availability of those commodities in district, sub-
districts, and community facilities and private drug stores. Stakeholders provided recommendations regarding 
the areas of assessment along with susequent discussion of the results and identification of priority actions. 
NATIONAL ASSESSMENT 
Document review of policies, guidelines,  
and use of 13 life-saving commodities 
Policy documents, policies, service delivery guidelines and 
circulars were collected and reviewed, complemented by 
searches for drug manufacturers at www.bddrugs.com 
and pharmaceutical companies’ web sites, as well as 
www.dgda.gov.bd, the Directorate General of Drug 
Administration’s web site (Appendix 1). These document 
reviews and searches were further complemented by 21 
in-depth interviews with representatives from MoHFW, 
professional associations and bodies, development 
partners, pharmaceutical companies, and NGOs, for 
clarification and greater detail about the drug and 
commodity landscape in Bangladesh. The findings from 
these searches and interviews combined to described the 
availability of the 13 recommended commodities, as well 
as related policy gaps, existing procurement mechanisms, 
manufacturing capacity, quality assurance guidelines and 
policies including product packaging, distribution and 
logistics, costs for end users, and financing. These 
activities provided mechanisms for engaging national and 
regional stakeholders and professional associations in 
ensuring supplies, identifying national priorities, and 
information gaps. 
Availability of the 13 life-saving commodities 
District, sub-district and community public facilities as 
well as private drug stores were visited to determine if the 
13 recommended commodities were available. Public 
drug stores were also visited to assess commodity 
availability, stock outs, and drug storage (including humidity and temperature control and refrigeration). A 
checklist was used to collect this information. Fifteen government facilities from three districts were visited 
including three District Hospitals, two Maternal and Child Welfare Centers (MCWCs), five Upazila Health 
Complexes (UHCs), four Union Health and Family Welfare Centers (UH&FWCs), and one Community Clinic (CC). 
Twenty-seven private drug stores were visited for information on drug availability, indications for which they are 
sold, and price; 16 of the 27 drug stores were at the district level and 11 were at the sub-district level. 
 
 
DOCUMENTS REVIEWED 
• Drug Policy of the Government  
of Bangladesh, MoH&FW 
• Quality Manual of Directorate General  
of Drug Administration, Bangladesh, 
MoH&FW 
• DGHS and DGFP operation plan 2011-2016, 
MoH&FW 
• “Training Manual of Use of Misoprostol  
to Prevent Postpartum Hemorrhage (PPH),” 
MoH&FW, USAID, EngenderHealth. 
• “Information Kit on Use of Misoprostol  
to Prevent PPH at Home Delivery,” MoH&FW 
and EngenderHealth 
• “National Protocol for Providing Loading Dose 
of Magnesium Sulphate (MgSO4)  
by the Community Level Service Providers,” 
MoH&FW, Obstetrical and Gynecological 
Society of Bangladesh (OGSB), 
EngenderHealth, Maternal and Child Health 
Integrated Program (MCHIP), and  
Population Council 
• “Family Planning Manual,” Directorate 
General of Family Planning (DGFP), MoH&FW  
• Trainer’s Handbook, “Active Management  
of Third Stage of Labor,” MoH&FW 
• Minutes of National Core Committee, 
Neonatal Health (NCC-NH), MoH&FW 
• Minutes of National Technical Committee 
(NTC), DGFP 
• Revised supply manual (2013), DGFP 
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STAKEHOLDER ENGAGEMENT 
A half day national workshop on 8 October 2013 in Dhaka with 22 policymakers, program managers, 
regulators, pharmaceutical industry representatives, and other stakeholders shared and discussed the findings 
of the assessment and identified priority activities for implementing the UN Commission’s recommendations 
within the Bangladeshi context. 
In addition to Population Council’s presentation, two other organizations presentated information on maternal 
and neonatal health commodity issues.   
The sessions enabled the Council to engage with DGFP, DGHS, and other stakeholders, to sensitize them to 
the Commission’s recommendations and exploring their introduction in Bangladesh, as well as providing an 
opportunity for developing recommendations that emerged from the workshop and discussing them. 
 
 
Workshop participants 
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Results 
The findings of this report triangulate the results from the review of policy documents, in-depth interviews, at 
facility and drug store validation assessments, the validation workshop, and findings from the efforts to 
engage policy makers, program managers, and other stakeholders in implementation of the UN Commission 
recommendations. 
NATIONAL DRUG POLICY 
Drug policies and guidelines 
The Directorate General of Drug Administration (DGDA), a 
division of MoHFW, is Bangladesh’s Drug Regulatory Authority. 
Interviews with DGDA officials revealed that it controls and 
regulates production, distribution, sale, and use of any drugs in 
the country. DGDA’s primary responsibility is to ensure that drugs 
are safe, efficacious, and of good quality. The National Drug 
Policy was formulated in 1982, and currently the Drugs Act 1940 
(XXIII of 1940) and Drugs (control) Ordinance 1982 (VIII of 1982) 
regulates registration, manufacturing, distribution, sale, 
importation, and exportation of any drugs in Bangladesh.  
All drugs, medicines, and other mechanical substances in final 
dosage forms manufactured, imported, distributed, marketed, or consumed in Bangladesh must be 
registered with DGDA for the specific dosage form and strength recommended by the Drug Control 
Committee (of DGDA). An important objective of the National Drug Policy is to make good quality drugs 
available at affordable prices, and therefore the policy requires quality assurance at different stages—
manufacturing, transit, and storage, with testing at different times before it reaches the end user.   
Interviews with policy makers and program mangers suggest that those responsible for implementing 
maternal health policies and services were not aware of the specifics of maternal health commodity policies 
and the UN Commission report and its recommendations. A few stakeholders, particularly the international 
development organizations and UN agencies, are aware of UN Commissions’ recommendations. 
Drug registration, indications, dose forms and presentations, and essential drugs list 
All 13 life-saving commodities are registered in Bangladesh with the exception of female condoms. Some of 
the commodities are not registered in the specific dose forms needed for particular MNH conditions or 
indications. A feasibility and acceptability study of the female condom by Social Marketing Company 
produced results that were not compelling enough to merit its introduction; policymakers and program 
managers suggested that the female condom would not have substantial uptake in Bangladesh.   
Oxytocin and magnesium sulphate are reported as registered and in 
use throughout the country for a long time. Oxytocin is registered for 
induction of labor and PPH prevention and treatment, available in 5 
iu/1ml ampoules, for both IM and IV injections, and in tablet form. 
Only one pharmaceutical company manufactures oxytocin tablet, and 
it is perceived as less effective than injection for the same indications. 
Service delivery guidelines (SDGs) for oxytocin are in place and 
followed in all facilities.  
Magnesium sulphate (MgSO4) is registered for prevention and 
treatment of severe pre-eclampsia (SPE) and eclampsia and is 
available at 49.3% w/v in 5 ml ampule (2.46 gm) and 4% w/v in 16.4 
mmol or 4.0 gm/100 ml solution for injection and infusion (IV/IM) forms (Table 3a and Table 3b). Although 
MgSO4 is registered and used for preventing and treating SPE and eclampsia, it is not available for this 
Oxytocin supply at a facility 
Oxytocin tablets 
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indication as a single loading dose (10 mg IV/IM) at the community level. Two studies, at the request of the 
National Technical Committee, are operationalizing and assessing the ability of community service providers 
to detect, prevent, and treat SPE and eclampsia with a single loading dose of MgSO4 before referral. 
Magnesium sulfate SDGs, for use by providers in community facilities, have been developed by MoHFW, the 
Obstetrical and Gynecological Society of Bangladesh, EngenderHealth, and Save the Children, and are being 
tested1. 
Misoprostol is registered, in two tablet dose forms (100 mcg, and 200 mcg), for gastrointestinal indications. 
Recently manufacturers’ brochures have included indications such as labor induction, PPH prevention and 
treatment, abortion induction, abortion incompletion, miscarriage, postabortion care, and intrauterine fetal 
death for which cervical ripening or softening is required.   
Although WHO, FIGO, and other professional bodies have recommended 600 mcg of Misoprostol for PPH 
prevention and management, the dosage approved by the National Technical Committee is 400 mcg. The 
National PPH Prevention Task Force and other relevant stakeholders recommended the lower dose based on 
Bangaldeshi women’s shorter stature and lower weight, but whether 400 mcg effectively prevents or treats 
PPH has not been evaluated. Anecdotal evidence suggests the 400 mcg dosage is ineffective, meriting its re-
evaluation. Single 400 mcg doses are available in individual packages for PPH prevention and treatment. 
Misoprostol 400 mcg is being scaled up in phases in another 18 districts. DGFP has included procurement 
(1.8 million pills or the equivalent of 0.9 million doses have already purchased) and distribution of 
Misoprostol in its operational plan (OP), and SDGs are available2, and Misoprostol tablets are now included 
in the country’s Essential Drug List (Appendix 2). 
As in other developing countries, fatality rates for severe bacterial infections in neonates (neonatal sepsis) 
are high in Bangladesh, partially due to the unavailability, or late or inadequate administration, of necessary 
antibiotics3,4. The UN Commission identified the three (procaine benzyl penicillin, gentamicin sulphate, 
ceftriaxone) most cost-effective antibiotics for neonatal sepsis. WHO recommends antibiotic treatment with 
procaine benzyl penicillin and gentamicin as initial therapy for presumptive treatment in newborns at risk of 
bacterial infection5. WHO recommends intramuscular injections (IM) of 50 mg/kg body weight of ampicillin 
(or a comparable penicillin such as procaine benzyl penicillin) every six to eight hours, depending on age, 
plus 7.5 mg/kg body weight of gentamicin (or another comparable aminoglycoside), divided twice daily for at 
least 10 days, as the standard therapy6. WHO also recommends, as a secondary therapy, daily injection of a 
single dose of ceftriaxone7 alone, of 50 mg/kg body weight for all newborns except those older than one 
week and weighing more than two kgs. In those slightly older and heavier newborns, the daily dose is 
increased to 75 mg/kg for 10 days.8 
In Bangladesh amoxicillin is available in many forms—powder for suspension, drops, tablet and injection—for 
pneumonia treatment. Procaine benzyl penicillin, gentamicin sulphate, ceftriaxone, and amoxicillin are each 
registered and indicated for newborn sepsis and other life-threatening infections. Procaine benzyl penicillin, 
gentamicin sulphate, and amoxicillin are listed in the EDL, but ceftriaxone is not (Appendix 2). The available 
doses for procaine benzyl penicillin are procaine penicillin 3 lac and benzyl penicillin 1 lac/vial for IM 
injection; 20 mg and 80 mg of gentamycin sulphate for IM/IV injection and 250, 500, 1,000, and 2,000 mg 
of ceftriaxone for IM/IV injection. Amoxicillin is available in the dose forms of 100 mg/1ml drop, 125 mg/5 
ml suspension, 250/500 mg/vial IM/IV injection and 250 mg/tablet dispersible tablet. SDGs are available 
                                                                        
 
1  MoHFW, OGSB, Save the Children (MaMoni project), and EngenderHealth. 2011. Guideline for prevention and management of pre-eclampsia 
and eclampsia at the Community. Guideline for community level service providers. EngenderHealth: Dhaka.     
2  MoHFW, EngenderHealth, Bangladesh and The National PPH Prevention Task Force. 2009. Guideline on Misoprostol Use in Bangladesh to 
prevent PPH at the Community level. EngenderHealth: Dhaka. 
3  Thaver D, Zaidi AK. Burden of neonatal infections in developing countries: a review of evidence from community-based studies. Pediatric 
Infectious Disease Journal. 2009;28(S1):S3–S9. 
4  Neonatal sepsis web page. Merck Manual website. Available at:  
www.merckmanuals.com/professional/pediatrics/infections_in_neonates/neonatal_sepsis.html#v1092175.  
5  Procaine benzyl penicillin is not recommended as first‐line treatment for neonatal sepsis except in settings with high neonatal mortality, 
when given by trained health workers in cases where hospital care is not achievable. 
6  WHO. Management of the Child With a Serious Infection or Severe Malnutrition: Guidelines for Care at First Referral Level in Developing 
Countries. Geneva: WHO; 2000: 62. 
7  WHO recommends not to administer with calcium and avoid in infants with hyper-bilirubinemia. 
8  Saez-Llorens X, McCracken GH. Clinical pharmacology of antibacterial agents. In: Remington JS, Klein JO, eds. Infectious Diseases of the 
Fetus and Newborn Infant. Philadelphia: W.B. Saunders Company; 2001: 1419–1466. 
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for all four drugs. During the sixth meeting of DGHS’s National Core Committee for Neonatal Health (NCC-NH) 
(2 September 2013) including dispersible amoxicillin tablet in the EDL was suggested9. Similarly, DGFP’s 
61st National Technical Committee (26 November 2013) approved amoxicillin dispersible tablets for the 
Dietary and Drug Supply (DDS) Kit10 of primary health and FP facilities for treating neonatal sepsis. 
For women at risk of pre-term delivery within seven days, WHO recommends a single course of 
corticosteroids between 24 weeks and 34 weeks of gestation.11 A single course of antenatal corticosteroids 
(ANCS) should be administered to women with premature rupture membranes before 32 weeks of gestation 
to reduce risk of pre-term respiratory distress syndrome (PTRDS), perinatal mortalities, and other morbidities. 
Dexamethasone sodium phosphate and betamethasone sodium phosphate are the two ANCS’s 
recommended for accelerating fetal lung development in threatened pre-term birth. WHO, NIH, ACOG, RCOG, 
and WAPM list both as effective drugs for preventing complications of prematurity, using either a dosage of 
24 mg of dexamethasone IM injection (4 doses of 6 mg 12 hours apart) or 24 mg of betamethasone IM 
injection (2 doses of 12 mg 24 hours apart)12,13. As of April 2013, the 18th edition of the WHO Model List of 
Essential Medicines, which for the first time includes antenatal corticosteroids, lists only dexamethasone 
sodium phosphate for fetal indications14. 
The ingredients for antenatal corticosteroids (dexamethasone sodium phosphate and betamethasone 
sodium phosphate) are registered in Bangladesh in different dose forms and for various indications, but not 
for pre-term respiratory distress syndrome (Table 3a and Table 3b). SDGs for the other indications are 
available, but not for pre-term respiratory distress syndrome. Dexamethasone sodium phosphate and 
betamethasone sodium phosphate are registered as 0.5 mg tablet, 0.1% eye drop, 0.05% eye ointment, and 
5 mg injection (only dexamethasone) dose forms for various indications, but not in 6 mg dose form as 
injection, which is indicated for pre-term respiratory distress syndrome. Although dexamethasone and 
betamethasone are listed in the EDL, 6 mg dose is not. DGHS’s sixth National Core Committee for Neonatal 
Health meeting approved introduction and scale up of 6 mg IM injection of dexamethasone for pre-term 
respiratory distress syndrome at the facility and community levels15. Pilot testing is ongoing in one district for 
assessing the feasibility and efficacy of ANCS in pre-term respiratory distress syndrome. Save the Children is 
working with DGHS, DGFP, and pharmaceutical companies to make the available dose form and include 
SDGs. 
Chlorhexidine digluconate, a broad spectrum antiseptic, is commonly used worldwide for various indications.  
WHO added 7.1% Chlorhexidine digluconate (delivering 4% Chlorhexidine) to the 2013 Model List of 
Essential Medicines for Children under Specific Medicines for Neonatal Care (Section 29) for neonatal cord 
care. Chlorhexidine cord cleansing (7.1% chlorhexidine digluconate) should not to be confused with other 
Chlorhexidine interventions using Chlorhexidine gluconate, such as solution for vaginal cleansing (0.16%–
0.60%), neonatal skin wiping (0.16%–0.60%), eyewash (0.05%), dental wash (0.12%), or preoperative skin 
cleansing (2.0%).  
Chlorhexidine gluconate is registered in different dose forms for various indications in Bangladesh, but not 
for newborn cord care; it is listed in the EDL for the other indications (Appendix 2), with SDGs available. 
Although they are not effective for cord care, the available dose concentrations are widely used in 
Bangladesh for newborn cord cleansing. The appropriate dose form (7.1%, according to WHO) for cord 
cleansing has been shown to be highly effective in the region: Three community-based randomized control 
trials in Nepal, Bangladesh, and Pakistan resulted in Chlorhexidine cord cleansing’s substantial reduction of 
neonatal mortality in all three countries, by 24 percent in Nepal, 20 percent in Bangladesh, and 38 percent 
                                                                        
 
9  DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS. 
10  DDS Kit is a box containing 26 pre-selected essential drugs, and dietary items to be dispensed by the community-based facility level service 
providers at UH&FWCs for patient management. Each month they receive certain number of DDS Kits from the central warehouse. 
11  Threatened pre-term birth can be characterized by four signs and symptoms that include i) fluid leaking from vagina (rupture membrane); ii) 
painful uterine contractions; iii) antepartum haemorrhage (vaginal bleeding); and iv) signs and symptoms of severe pre-eclampsia and 
eclampsia. 
12  WAPM: Guideline for the use of antenatal corticosteroids for fetal maturation (2008).  (Xavier Miracle1, Gian Carlo Di Renzo, Ann Stark, 
Avroy Fanaroff, Xavier Carbonell- Estrany1 and Erich Saling. J. Perinat. Med. 36 (2008). New York.) 
13  Cochrane summary: Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. 
14  WHO Model List of Essential Medicines, 18th list (April 2013). 
15  DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS. 
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in Pakistan. Chlorhexidine cord cleansing also reduced severe cord infection by 75 percent in Nepal, 65 
percent in Bangladesh, and 42 percent in Pakistan.  
DGHS’s sixth National Core Committee for Neonatal Health meeting, prior to the stakeholder meeting, was a 
turning point, at which application to all newborn umbilical stumps at birth16 of 7.1% aqueous solution of 
Clorhexidine gluconate, regardless of place of birth (home or facility), was approved and listed as part of the 
essential neonatal care (ENC) package. The committee also suggested including 7.1% Chlorhexidine in the 
EDL. Similarly, DGFP’s 61st National Technical Committee meeting approved Chlorhexidine 7.1% aqueous 
solution’s inclusion in primary health and FP care facilities’ Dietary and Drug Supply (DDS) Kits for newborn 
cord care. Save the Children is scaling it up in one district, and SDGs are being prepared. Dialogue is being 
initiated with reputed pharmaceutical companies to encourage the production and marketing of aqueous 
solution of 7.1% Chlorhexidine nationwide.17   
Almost half of all newborn deaths occur within the first 24 hours, with most resulting from birth asphyxia due 
to intra-partum complications. This condition, manifesting as newborn failure to establish breathing after 
birth, is responsible for one quarter of all newborn deaths worldwide each year18. Many of these deaths 
could be easily prevented with basic neonatal resuscitation, which requires tactile stimulation, a neonatal 
bag and mask, suction device, and a resuscitation training mannequin. With this basic equipment and 
effective pre- and in service training, successful resuscitation of newborns is possible for about 30 percent of 
cases otherwise resulting in death among full term babies, and for five to ten percent of pre-term births19.   
The WHO Essential Medical Devices List, which is currently being 
updated for priority interventions for Maternal, Neonatal and Child 
Health, includes neonatal resuscitators (self-inflated bag and mask), 
suction devices, and resuscitation training mannequins. The 
resuscitation device is registered in Bangladesh, but there is no 
Essential Medical Devices List in Bangladesh. The device has been 
donated by USAID in selected districts under the Helping Babies 
Breathe (HBB) program implemented by DGHS, ICDDR,B, and Save 
the Children, with technical assistance from UNICEF. SDGs are 
available. 
Oral Rehydration Salts (ORS), 
introduced in Bangladesh by 
ICDDR,B, are widely available 
and in use. ORS is registered 
and incorporated into the EDL 
for diarrheal treatment of children, with SDGs. ORS is over-the-counter, 
has a strong safety profile, and has no cold chain storage requirements. 
The standard treatment guidelines for diarrhea in Bangladesh follow the 
WHO-UNICEF Integrated Management of Childhood Illnesses (IMCI) 
guidelines. Recently, zinc sulphate monohydrate was added for diarrhea 
management as an adjunct therapy, as it has proven effective in 
reducing diarrheal episodes, as well as their duration. Zinc is registered 
in Bangladesh, listed in the EDL, with SDGs available. ORS in 
Bangladesh is available in various forms mixed with nutritional components (under brand names such as 
ORSaline-N, ORSaline Fruiti, Tasti Saline), while zinc sulphate monohydrate is available in tablet and syrup, a 
10/20 mg/tablet or 5 ml syrup. New WHO and UNICEF formulations of ORS have Sodium Chloride 1.30 gm, 
Potassium Chloride 0.75 gm, TriSodium Citrate/Dye Hydrate 1.45 gm, and Glucose/Anhydrous 6.75 gm. 
                                                                        
 
16  Guidelines suggest single application of 7.1% Chlorhexidine aqueous solution followed by dry cord care. 
17  DGHS, MoHFW.2013. Minutes of the 6th meetings of the National Core Committee for Neonatal Health. Dhaka: DHGS. 
18  Black, R., S. Cousens, H.L. Johnson, et al. 2010. Global, regional, and national causes of child mortality in 2008: a systematic analysis. 
Lancet 375(9730): 1969–1987. 
19  Wall, S.N. et al. 2009. Neonatal resuscitation in low resource settings: what, who, and how to overcome challenges to scale up. International 
Journal of Gynecology and Obstetrics 107: S47-S64. 
Resuscitation device 
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The female condom is not registered in Bangladesh, and policy makers and program managers believe its 
acceptance and use would not be significant. Contraceptive implants and emergency contraceptive pills 
(ECPs) are, however, registered and included in DGFP’s contraceptive method mix. SDGs for these methods 
are available. Two types of contraceptive implants are available: a three year single rod implant with 68 mg 
etonogestrel, and a five year two rod implant, each containing 75 mg levonorgestrel.  
In Bangladesh ECPs are an over-the-counter product manufactured by several 
pharmaceutical companies in the country. DGFP’s 61st National Technical 
Committee meeting in August 2013 approved a single dose (1.5 mg) ECP 
regimen, instead of a two dose regimen of 0.75 mg/dose 12 hours apart, with 
the period of time during which women can effectively take ECPs increased to 
from 72 hours to 120 hours after unprotected sex. Although the drug is not listed 
in the EDL or in the Dietary and Drug Supply Kits for primary health care facilities, 
SDGs are available. 
 
DRUG AVAILABILITY  
Government facilities and drug stores 
A team visited 15 public sector facilities between August and 
September 2013. In-depth interviews with policy makers, 
program managers, and other stakeholders revealed that the 
13 commodities, with the exception of female condoms, can 
generally be found at health facilities at district, sub-district, 
and primary care levels. Some drugs are not available in 
WHO recommended doses for maternal and neonatal 
indications, and drugs were not available on the day of the 
visit at some facilities, and shortages were reported. 
TABLE 1:  Maternal and neonatal health drugs and commodities available in government facilities, by facility type 
Maternal and neonatal 
drug or commodity 
Number of facilities, by type 
Total  (%) District Sub-district Community 
DH MCWC UHC UH&FWC CC 
Oxytocin 1 2 4 020 021 7  (47%) 
Misoprostol 1 2 3 122 0 7  (47%) 
Magnesium sulphate 3 1 2 023 021 6  (40%) 
Injectable antibiotics 2 0 3 020 021 5  (33%) 
Antenatal corticosteroid 0 0 0 020 021 0  (0%) 
Chlorhexidine 0 0 0 0 0 0  (0%) 
Resuscitation device 2 1 3 2 020 8  (53%) 
Amoxicillin 3 2 4 4 1 14  (93%) 
ORS 3 0 4 1 1 9  (60%) 
Zinc 3 1 2 1 1 8  (53%) 
Female condom - - - - - - 
Contraceptive implants 224 2 3 126 020 8  (53%) 
Emergency contraceptive pill 0 0 0 0 0 0  (0%) 
N 3 2 5 4 1 15 
‘0’=Not available;  ‘---‘=Never introduced;  DH=District hospital;  MCWC=Mother and Child Welfare Center;  
UHC=Upazila Health Complex; UH&FWC=Union Health and Family Welfare Center, CC=Community Clinic 
                                                                        
 
20  According to MoHFW policy, these centers are not allowed to provide this drug. 
21 Service providers at this level are not allowed to administer any injectable antibiotic. 
22  Misoprostol is in the process of scaling up with only 10 districts with community distribution thus far. 
23  Loading dose is approved to provide from these centers and piloting is continuing. 
24 These centers can provide these services only when they are designated or upgraded to provide the services. 
Emergency 
Contraception Pill  
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Corticosteroids (dexamethasone sodium sulphate and betamethasone sodium sulphate) and Chlorhexidine 
were not found in MCWCs, UH&FWCs, and CCs. Where they were available, they were not in the right dose 
forms for pre-term respiratory distress syndrome or newborn cord care. Resuscitation devices were available 
in all facilities where health professionals and workers were trained under Helping Babies Breathe (see 
Table 1) in 19 districts.  
Antibiotic injections (amoxicillin) in different dose forms were found in most facilities, except one UHC, and 
no MCWCs. (Availability of ORS, zinc sulphate, and contraceptive implants are presented in Table 1.) ECPs 
were not available in any facilities due to supply shortages. Although some UH&FWCs are ready to provide 
normal delivery services, they do not have any drugs except those in the DDS Kit (Appendix 3) such as 
Chlorhexidine, misoprostol, oxytocin, and MgSO4 (Table 1).  
Discussions with facility managers, service providers, and store keepers 
revealed that SDGs for some of the 13 commodities are lacking and 
providers depend on the materials provided by pharmaceutical companies.  
No facility received any SDG from national authorities, and providers must 
rely on their training and other resource materials. Providers indicated that, 
since their initial training on these commodities, they were able to dispense 
and administer them. Nurses sought support from doctors if they needed 
additional guidance. All visited facilities stored their drugs, including oxytocin, 
on shelves. Only MCWCs stored oxytocin in refrigerators.  
Most drugs (especially injectable or intravenous infusions) are administered 
by physicians and trained service providers. Most providers have pre-service 
training and on-the-job training on clinical decision making and drug administration. The interviews revealed 
that, due to a lack of coordination between drug store keepers and providers, providers are unaware of 
which drugs and commodities are available in facility stores. Also, many providers reported an inability to 
estimate the consumption rate of drugs and commodities in their facilities because they lack data. 
Private pharmacies and drug stores 
Twenty-seven private drug stores and pharmacies were visited in August and September 2013 at district, 
sub-district, and community levels to determine drug and commodity availability. At all private drug stores, 
the most available drugs were amoxicillin, zinc, and ORS: All drug stores and pharmacies had these drugs 
stocked on the day of the visit. 
TABLE 2: Maternal and neonatal health drugs and commodities available in private drug stores and pharmacies, by district 
Maternal and neonatal drug  
or commodity 
District 
Total (%) 
Gazipur Zinaidah Comilla 
City/ 
Sadar 
Sub-district 
City/ 
Sadar 
Sub-district 
City/ 
Sadar 
Sub-
district 
Oxytocin for PPH 4 0 5 5 3 2 19 (70%) 
Misoprostol for PPH 3 2 7 5 2 3 22 (82%) 
Magnesium sulphate (MgSO4) for severe 
pre-eclampsia/eclampsia 
2 0 5 5 0 0 12 (44%) 
Injectable antibiotics for newborn sepsis 3 2 7 5 3 3 23 (85%) 
Antenatal corticosteroids for PTRDS 025 025 025 025 025 025 0 (0%)25 
Chlorhexidine for newborn cord care 025 025 025 025 025 025 0 (0%)25 
Resuscitation devices for newborn 
asphyxia 
026 026 026 026 026 026 0 (0%)26 
Amoxicillin for pneumonia 6 3 7 5 3 3 27 (100%) 
ORS for diarrhea 6 3 7 5 3 3 27 (100%) 
Zinc for diarrhea 6 3 7 5 3 3 27 (100%) 
Female condom 026 026 026 026 026 026 0 (0%)26 
Contraceptive implants 027 027 027 027 027 027 0 (0%)27 
Emergency contraceptive pill 1 1 5 5 3 2 17 (63%) 
N 6 3 7 5 3 3 27 
                                                                        
 
25  They sell different dose forms 
26  Not available 
27  Not authorized to sell 
Oxytocin stored  
at room termperature 
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Other drugs such as oxytocin, misoprostol, and MgSO4 were 
less available. Almost all drug sellers report low demand for 
Oxytocin, Misoprostol, and MgSO4 and that the drugs require 
a doctor’s prescription, making their sales volumes 
dependent on the extent to which doctors prescribe them. 
Drug store keepers explained that they lose money if drugs 
expire while on their shelves due to slow sales, and thus they 
do not stock them. In 15 percent of drug stores, injectable 
antibiotics were not found at the day of the visit. Similarly, 
ECPs were not found in 37 percent of drug stores. This 
pattern of unavailability was similar for all city or Sadar, sub-
district, and community levels. No seasonal variations were 
observed except for SMC ORSaline-N: Most drug sellers indicated that the demand for Social Marketing 
Company’s ORSaline-N peaks in summer and quickly goes off the market due to increased demand. ORS 
produced by other companies are available in all seasons. Dexamethasone and betamethasone and 
chlorhexidine are available in all drug stores, but in different dose forms and unsuitable for pre-term 
respiratory distress syndrome and newborn cord care, respectively. Resuscitation devices and female 
condoms were not available in any of drug stores. MoHFW policy does not allow private drug stores to sell 
contraceptive implants. 
A substantial price difference was observed for all drugs according to place of manufacture, whether in 
Bangladesh or overseas. Drugs manufactured overseas or by foreign companies in Bangladesh are more 
expensive than those produced locally, while no significant differences in prices were observed among dugs 
manufactured in Bangladesh. According to drug sellers, the price of most drugs (except injectable antibiotics) 
was affordable to end users. Drug sellers were unable to rate the quality of their different products and rely 
on the opinions of prescribing physicians.  
Maintenance of a cold chain of storage for oxytocin’s stability is crucial, yet two out of nine drug stores in 
Gazipur district, six out of 12 in Zinaidah district, and one out of six in Comilla district stored oxytocin on 
shelves rather than in the refrigerators. No drug seller had a refrigerator on the premises. All other drugs 
were stored on shelves at room temperature as well. 
LOGISTICS AND SUPPLY ORDERING  
Interviews with policymakers and program managers reveal that 
centralized and decentralized procurement processes for 
commodities and logistics each exist within MoHFW. MoHFW 
follows the World Bank procedure for procuring drugs and 
commodities, through an open bidding process, whereby the 
lowest bidder is awarded the supply contract if they have the 
requisite qualifications and fulfill the specifications in the tender.  
Procurement is by two separate MoHFW systems. In the public 
health sector, most procurement is by the Centre for Medical Store Depot, at the central level, with a few 
items purchased at district levels. Drugs purchased at the district level are directed by a committee of the 
Civil Surgeon, Resident Medical Officer, Gynecological and Obstretics Consultant, and Surgery Consultant 
that estimates purchase volumes based on the previous year’s utilization of the individual product. Usually, 
however, drugs and commodities are ordered at the national level, stored at the central warehouse, and 
then distributed to districts and facilities. There is no scope for local procurement, at the sub-district level, 
for health departments. All drugs and commodities are forecasted at the central level according to the lower 
level facilities’ requests for each commodity. 
The FP sector has an extensive process for procurement and logistics. Typically, a Director executes a need 
assessment of drugs and commodities based on utilization rates, includes it in the appropriate year’s 
procurement plan, and the information is loaded to the MoHFW web portal. The Ministry provides approval 
for procurement and DGFP issues the tender, with a tender evaluation committee (with the Director General, 
Private drug store 
Register and reporting form 
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Director of Logistics and Procurement, the respective Director, and two members from the other two 
ministries) evaluating the subsequent proposals and ranking them on their technical and financial aspects. 
The central warehouse mainly procures DDS Kits (Appendix 3), misoprostol, oxytocin, and contraceptives 
with the exception of ECPs. A quality control team verifies and certifies the quality of each drug and 
commodity according to the supply order, after which payment is made. Distribution is usually according to 
forms 728 and 7b29 and calculated for estimated consumption in the coming three months. Each facility then 
receives their allocated number of DDS Kits containing 26 drugs and commodities per kit. Contraceptive 
forecasting and procurement occur at the central level, with storage is at the central warehouse, followed by 
distribution to regional warehouses and then to upazila stores, from which facilities and workers collect 
commodities. In all facilities including warehouses, at least one month’s supply of drugs and commodities 
are mandated, unless there is a central shortage of a supply. Contraception and DDS Kit distribution is 
usually in accordance with the ‘push’ method, permanent methods are procured ‘on demand’ by facilities. All 
facilities record supply and use of drugs and commodities in registers. DGFP’s LMIS system tracks the 13 UN 
commodities. SIAPS is working with DGHS to develop a similar system. 
Private and NGO clinics have their own systems for commodity purchase and supply according to their 
needs. Private and NGO clinics can collect contraceptives from their local authorities and, if registered with 
the FP department, can provide FP services. 
Most respondents in facilities were unaware of the national quality control guidelines and assurances. 
Respondents from pharmaceutical companies did, however, mention that DGDA quality control guidelines 
require them to have their own Standard Operating Procedures (SOPs) and ISO certifications. Service 
providers in facilities mentioned that end users are not willing to pay for drugs and commodities. In addition, 
they also mentioned low demand for oxytocin, misoprostol, MgSO4, ANCS, zinc, and ECP.  
MANUFACTURING AND DISTRIBUTION  
Several domestic pharmaceutical manufacturers produce most of the 13 life-saving commodities; 
resuscitation devices, contraceptive implants, and female condoms are the only products not manufactured 
locally. In this study two manufacturers were visited, and relevant persons interviewed. The two companies 
visitied manufacture most of the listed drugs and commodities available in Bangladesh (Table 3b). Drugs 
and commodities manufactured by local pharmaceutical companies are available at www.bddrugs.com. 
Contraceptive implants (Implanon) are imported from Organon, MSD, and Netherland, and are distributed by 
Janata Traders. 
Resuscitation devices were donated by USAID through the Helping Babies Breathe program. Many 
companies do not manufacture hormonal preparations such as contraceptive pills or injectables—only one 
pharmaceutical company manufactures injectable contraceptives—but at least four companies produce 
ECPs. No pharmaceutical company produces Chlorhexidine and antenatal corticosteroids in appropriate 
dose forms, although they have preparations in different dose forms for other indications. Only four local 
companies (Table 3b) manufacture and market oxytocin, as its need for cold chain production and storage 
require more specialized resources and skills. 
The prices of local products are regulated by DGDA. Without DGDA approval no pharmaceutical company can 
set a price for their drugs or commodities. Companies adhere to drug policy rules and regulations when 
setting their prices, which results in no excessive pricing differences for drugs produced by various domestic 
companies; drugs manufactured by foreign companies do not adhere to those pricing guidelines.  
Pharmaceutical companies generally teach storage practices to drug distributors but not to drug stores 
themselves, which has resulted in difficient knowledge of correct product storage. Although there is no 
visible public-private partnership in pharmaceutical production, DGDA has expressed an interest in such 
efforts. 
                                                                        
 
28  Monthly issue, distribution and balanced sheet, central and regional warehouse 
29  Upazila monthly supply, distribution and stock balance report 
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QUALITY CONTROL AND ASSURANCE  
Bangladesh’s National Drug Policy requires each pharmaceutical 
company to have quality control (QC) and quality assurance (QA) systems 
for monitoring their entire manufacturing process, from acquisition of 
raw materials through completion to finished product. It also requires all 
pharmaceutical companies to have documented Standard Operating 
Procedures (SOPs) based on WHO-recommended current Good 
Manufacturing Practice guidelines for each product and unit process. 
These SOPs can include quality control laboratories or access to licensed 
medicine manufacturing facilities, equipment, qualified personnel, 
procedures, and references30,31. 
As part of the quality control program, the Bangladesh government 
established two drug testing laboratories in Dhaka and Chittagong 
districts. Findings from the interviews with drug authorities and 
pharmaceutical representatives reveal that these drug testing laboratories’ capacities are limited both in 
terms of manpower and logistics: They can only can test about 30 percent of Bangladesh’s 3,500 total 
products each year.  
Every medicine available for consumption must qualify its approved standards (specifications). The standard 
for a medicine should be indicated in the application meaning which pharmacopoeia they would follow (e.g. 
British Pharmacopoeia (BP), International Pharmacopeia (IP), United States Pharmacopoeia (USP), and 
European Pharmacopoeia (EPh), etc.). Recently, DGDA approved the National Pharmacopoeia, which was 
also approved by WHO. 
As the government has limited capacity to control the quality of all drugs, it is primarily a manufacturer’s 
responsibility to ensure quality, but DGDA is the National Regulatory Authority and is ultimately responsible 
for the regulation and quality assurance of all medicines. Initially, licensed manufacturers develop 
formulations and prepare samples of a medicine on trial and error basis in their own laboratory and test the 
samples following specifications of established Pharmacopoeia. They need to validate their test procedures 
and submit the samples to DGDA for testing and analysis in the Government Drug Testing Laboratory for 
registration with a certificate from their own test. The submitted samples must comply with their standard 
specification and passed by the Government Analyst32.   
Before confirming registration of a new product, DGDA sends a team of inspectors to assess the 
pharmaceutical company’s manufacturing facility, including their drug testing laboratories. Per public drug 
rules, DGDA inspects every manufacturing unit during renewal of their drug manufacturing licenses (every 
two years). DGDA also monitors the quality of marketed drugs by collecting samples at random from different 
drugstores and medicine markets and tests those drug samples in government laboratories. For imported 
medicines all distributors should have Free Sale Certificates of the National Regulatory Authority of at least 
one of the seven developed countries (UK, USA, Germany, France, Switzerland, Australia and Japan) or Good 
Manufacturing Practice (GMP) certificate from WHO. This procedure is followed to ensure the safety, quality, 
and effectiveness of the imported drug32. 
If any drug sample is declared substandard by the government analyst then the production, distribution and 
marketing of the respective batch of the drug is immediately suspended and instructions issued to the 
manufacturer to withdraw the batch from all channels by publishing withdrawal notices in at least two widely 
circulated daily newspapers. Simultaneously, investigations by DGDA inspectors examine the root causes. 
DGDA also lodges a case in the Drug Court against the responsible persons of the drug manufacturer for 
punitive actions. 
 
                                                                        
 
30  Drug Policy of the Government of Bangladesh, MoH&FW 
31  Quality Manual of Directorate General of Drug Administration, Bangladesh, MoH&FW 
32  Quality Manual of Directorate General of Drug Administration, Bangladesh, MoH&FW 
Pharmaceutical company 
Procedure Manual 
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PACKAGING  
Findings from the in-depth interviews indicate that separate packaging of all 13 commodities is not 
available. National workshop participants reiterated this fact. Many of the 13 commodities are provided in 
universal dose forms, and service providers must decide how much has to be given for specific MNH 
indications. Antibiotics for neonatal sepsis are available in various dose forms for drops, suspension, tablets, 
and injection, each in different concentrations not specifically packaged for neonatal sepsis, but which is 
simply mentioned as one of the indications on the packaging. Similarly, MgSO4 is available in solution and 
power for solution forms in different concentrations. There is no separate packaging for a loading dose of 10 
mg in a vial. Current available forms are 2.46 grams per 5 ml or 4 grams in per 100 ml vial, which means 
that four vials are required as a loading dose in the community before referral. 
All respondents in the national workshop, as well as most service providers, recommend a separate single 
dose packaging of these essential drugs. They suggest the same for a single dose of gentamycin for neonatal 
sepsis. The piloting of misoprostol for PPH prevention and treatment was conducted with separate packaging 
specifying the indication. The same procedure is due for scale up in 18 districts. The manufacturer was 
instructed to make separate packaging of 400 mcg tablets (200 mcg x 2) for PPH prevention. Similarly, 
pharmaceutical companies are required to have separate package of misoprostol with mifepristone for the 
specific indication of medical termination of pregnancy, and it is now on the market. No drug is included in 
existing bundles such as the delivery kit but there are ongoing discussions about its inclusion. Separate 
packaging had enormous support from all respondents, who feel that separate packing of appropriate doses 
would greatly improve correct indications and doses. 
FINANCING  
It is government policy to supply all dugs and commodities (including FP commodities) free of cost to those 
securing services either at facilities or through doorstep delivery31. In reality, service and drugs from facilities 
are not free of cost, with clients encountering considerable out-of-pocket expenses. They frequently must 
purchase drugs from private drug stores due to supply shortages or pay informal service fees33.   
Clients are charged for services within the private sector. NGOs charge subsidized rates. All interviewed 
respondents, workshop participants, and public facility service providers mentioned stated that end users 
are not willing to pay for drugs and commodities, and the ultra poor cannot pay for anything. Drug sellers, 
however, are of the opinion that, in terms of health expenditures and out-of-pocket expenses, the costs of 
MNH drugs and commodities on the open market are within most end users’ reach. The respondents also 
mentioned that there must be a safety net provided for the ultra poor. All respondents also felt that products 
should be included in conditional cash transfer coupons, vouchers, or other similar schemes, particularly the 
ongoing public sector maternal health voucher schemes. 
ENGAGING POLICY MAKERS, PROGRAM MANAGERS, AND OTHER 
STAKEHOLDERS   
As an initial activity of this engagement, two meetings with DGFP explored how to roll out the UN Commission 
recommendations. This was a follow up activity after the validation workshop that recommended forming an 
advocacy forum to ensure maternal and neonatal health drug and commodities are a cause that is taken up 
by relevant stakeholders. It was requested that Population Council take the responsibility for developing 
Terms of Reference of the forum. DGFP’s Director of Maternal and Child Health intends to call a bigger 
meeting and an effort is ongoing to create this advocacy forum. 
 
 
                                                                        
 
33  Rahman, L., U. Rob, R. Mahmud, A. Alim, I.A. Hena, M.N. Talukder and H. Rahman. 2012. A pay-for-performance innovation integrating the 
quantity and quality of care in maternal, newborn and child health services in Bangladesh. Dhaka: Population Council. 
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Challenges, Opportunities, Recommendations 
Interviews with policymakers, program managers, service providers, store keepers, drug sellers, and 
workshop participants revealed a number of challenges, opportunities, and recommendations: 
CHALLENGES 
• Shortages of all essential drugs and commodities in public health facilities; 
• Inappropriate storage of oxytocin (and consequential use of an ineffective drug during crucial medical 
events) is widespread; 
• Unavailability of antenatal corticosteroids in correct dose forms (6 mg injection) for pre-term respiratory 
distress syndrome; unavailability of Chlorhexidine in correct concentration (7.1%) for newborn cord care; 
provider use of inappropriate concentration; and lack of SDGs; 
• Unavailability of Magnesium Sulfate in appropriate dose forms and need for manufacturing a single 
loading dose for severe pre-eclampsia or eclampsia, and lack of interest from pharmaceutical companies; 
• Lack of advocacy with pharmaceutical companies for manufacturing less profitable but essential drugs in 
appropriate dose forms; 
• Lack of awareness of Emergency Contraceptive Pills due to lack of educational efforts; 
• Lack of knowledge and low use of zinc sulphate for neonatal diarrhea; 
• Absence of a forum at DGFP that advocates for mothers and ensures access to and use of essential 
maternal health drugs and commodities. 
OPPORTUNITIES 
• All 13 drugs and commodities are registered (except the female condom) are registered in the country in 
different dose forms, meaning that registration for different, altered dose forms is feasible. 
• The Directorate General of Drug Administration is very much in favor of ensuring the availability, quality, 
and affordability of essential maternal and neonatal health drugs and commodities. They requested an 
application for the approval of essential drugs in required dose forms. DGFP was requested to form an 
advocacy forum to ensure the availability of maternal health drug and commodities. Systems for Improved 
Access to Pharmaceuticals and Services (SIAPS) supported a Forecasting Working Group at DGFP. DGHS 
has a Supply Chain Coordination Forum where UN, WB, UNAIDS, MoHFW, and other stakeholders are 
partnered. 
• Chlorhexidine has already been approved by the Directorate General of Drug Administration in appropriate 
concentration, and DGHS’s National Core Committee for Neonatal Health and DGFP’s National Technical 
Committee approved its use in the vertical program. Social Marketing Company has reportedly began 
manufacture the drug, and Save the Children is piloting its use in one district. 
• DGHS’s National Core Committee for Neonatal Health and DGFP’s National Technical Committee have 
approved introduction and scale up of dexamethasone sodium sulphate 6 mg intramuscular injection for 
pre-term respiratory distress syndrome, for use both in facilities and within communities. 
• The Directorate General of Drug Administration issued letter for appropriate storage of oxytocin in all public 
health facilities, and DGHS and DGFP have also issued letter to all facilities. 
• Systems for Improved Access to Pharmaceuticals and Services (SIAPS) and other stakeholders are 
facilitating DGHS’s and DGFP’s quantification of the MNH commodities needed for facilities. DGFP has an 
LMIS system for tracking the 13 UN commodities. They have also proposed including Chlorhexidine and 
misoprostol in standard infant delivery kits. 
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• Participating respondents are concerned about the unavailability and inappropriate dose forms of MNH 
commodities, suggesting a wide basis of support for improved commodity availability. 
• The participating respondents are concerned about the use of low dose misoprostol for PPH prevention 
and treatment. 
• Social Marketing Company and Mayer Hashi of EngenderHealth initiated training for implant insertion and 
removal through private providers. 
RECOMMENDATIONS  
Maternal health 
• Misoprostol should be bundle with birthing delivery kits. 
• Advocacy with pharmaceutical companies should to manufacture a single loading dose of MgSO4 solution. 
• Participants have suggested assessing the effectiveness of 400 mcg versus 600 mcg misoprostol in 
preventing post-partum hemorrhage in the Bangladeshi context. 
• Essential drugs and commodities for mother should be made available in Union Health and Family Welfare 
Centers where normal vaginal deliveries are planned and conducted. 
Neonatal health 
• Chlorhexidine should be bundled with birthing delivery kits. 
• Resuscitation devices should be available in all districts, particularly in all facilities where deliveries are 
conducted. 
• Advocacy should be conducted with pharmaceutical companies to manufacture single dose of gentamycin 
injection and 7.1% Chlorhexidine. 
• Essential drugs and commodities for neonate should be made available in UH&FWCs where normal 
vaginal deliveries are planned and conducted. 
• Single dose injectable antibiotics should be manufactured and promoted for neonatal sepsis. 
• Educational efforts should be strengthened toward in increasing awareness of zinc use in diarrheal 
diseases. 
Family Planning commodities 
• DGFP should take initiatives to increase public awareness of avoiding unplanned pregnancy and ensure 
availability of ECPs in all facilities as well as to fieldworkers. 
General recommendations 
• Formation of a forum at DGFP to advocate ensuring access to and use of MNH drugs and commodities. 
• Further initiatives are necessary to ensure drug quality, appropriateness of dosage, and reliable availability 
in both the private and public spheres. 
• Directorate General of Drug Administration, DGFP, and DGHS should be regularly updated by active 
stakeholders on the global updates on maternal and neonatal health and other public health issues. 
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Table 3a: Policy, guidelines, and availability matrix of 13 life-saving maternal and neonatal health commodities in Bangladesh 
Name of 
commodity 
Regis
tered
? 
Indication? Available dose? 
Presentati
on? 
Listed in 
EDL? 
What is the policy? 
Service 
delivery 
guidelin
es exist? 
Availability 
Storing place? 
Who can 
administer? 
Procure
ment? 
Able to 
forecast 
supply needs? 
In 
country 
manufac
turing? 
Qualit
y 
assura
nce 
guideli
nes 
exist? 
Qualit
y 
contro
l lab 
exists? 
Stakeholder 
interest in roll 
out UN 
recommendati
on? 
Government facility? 
Private/Drug 
Store? 
Natio
nal 
Distric
t 
Subdi
strict 
Commu
nity 
Nati
onal 
Commu
nity 
Public Private 
Natio
nal 
Subna
tional 
Oxytocin Yes 
-induction 
of labor 
- PPHP & 
treatment 
5 iu/1ml 
ampule 
im/iv 
Injection & 
Tablet  
Yes 
-induction of labor 
- PPHP 
Yes Yes Yes34 Yes34 No Yes No 
Freeze
35 
Freeze
36 
Physician & 
midwifery 
nurses at 
hospitals 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
Misoprostol Yes 
- PPHP 
-Anti-ulcer 
-Abortive 
- Various 
indications 
100 mcg 
Tablet  Yes 
- 400 mcg for PPHP 
- community 
distribution by field  
workers 
Yes Yes Yes34 Yes34 No Yes Vary34 Shelf Shelf 
Field 
workers 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
200 mcg 
Magnesium 
Sulphate 
heptahydrate BP 
(MgSO4) 
Yes 
-prevention 
and 
treatment of 
SPE/E 
49.3% w/v in 5 
ml amp (2.46 
gm) 
iv/im 
Injection 
and 
Infusion 
Yes 
- use in SPE/E  
- piloting single 
loading dose at 
community  
Yes Yes Yes34 Yes34 No Yes No Shelf Shelf 
Physician & 
midwifery 
nurses at 
hospitals40 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
4% w/v in 100 
ml iv. Solu. 
Injectable 
antibiotics  
Yes 
- Newborn 
sepsis 
- Various 
indications 
Procaine 
penicillin 3 lac 
-f Benzyl 
penicillin 1 
lac/vial 
Powder 
for im 
Injection  
Yes 
- save lives due to 
life threatening 
infections  
Yes Yes Yes34 Yes34 No Yes Vary34 Shelf Shelf 
Physician & 
trained 
service 
providers 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
In
je
c
ta
b
le
 
a
n
ti
b
io
ti
c
s 
Procaine 
benzyl 
penicillin 
Gentamicin 
sulphate 
Yes 
- Newborn 
sepsis 
- Various 
indications 
20 mg 
im/iv 
Injection  
Yes 
- save lives from life 
threatening 
infections 
Yes Yes Yes34 Yes34 No Yes Yes34 Shelf Shelf 
Physician & 
trained 
service 
providers 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
80 mg 
 
Ceftriaxone Yes 
- Newborn 
sepsis 
- Various 
indications 
250 mg 
im/iv 
Injection  
No 
- save lives due to 
life threatening 
infections 
Yes Yes Yes34 Yes34 No Yes Yes34 Shelf Shelf 
Physician & 
trained 
service 
providers 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
500 mg 
1 gm 
2 gm 
Amoxicillin Yes 
- Pneumonia 
-various 
indication 
100 mg/1ml Drop 
Yes 
- save lives due to 
life threatening 
infections 
Yes Yes Yes34 Yes34 Yes Yes Yes Shelf Shelf 
Trained 
service 
provides 
Centrali
zed37 
Yes No Yes Yes38 Yes39 
Already in 
system 
125 mg/5ml Susp. 
250/500 
mg/vial 
iv/im 
Injection  
250 mg/tab DT 
Antenatal 
corticosteroids 
(ANCS) 
Dexamethasone & 
betamethasone41  
Yes 
-Various 
other 
indications 
 
5 mg/1 ml vial 
and other 
preparation in 
various dose 
forms 
Not available42 
im/iv/tab Yes 
-used in various 
indications 
-recently approved 
for PTRDS 
No43 Yes Yes44 Yes44 Yes44 Yes44 Yes44 Shelf Shelf 
Trained 
service 
providers 
Centrali
zed37 
Yes No Yes Yes38 Yes39 Interested 
                                                                        
 
34 Some places it is available and some places not. 
35 In most places they kept it in the shelf in normal temperature. 
36 In most of the places they kept it in normal temperature and found in shelf. 
37 Centralized procurement but if needed local level can purchase it from the local market from available fund. 
38 Companies follow the QA guidelines of that pharmacopeias from where the drug is originated or the ingredients are purchased. 
39 Both public and pharmaceutical have their own quality control laboratories (QC lab). GOB has two laboratories and has limited capacity and resources to check quality of all pharmaceutical products. There are 3500 pharmaceutical products. By two QC lab GOB can check only one-third products. About 
30% of the pharmaceuticals have their own QC lab and they provided QC certificate to the drug administration. It is alleged that QC measures are lacking both GOB and private companies. 
40 Trial is being conducted to administer loading dose of MgSO4 through community based facility level service providers 
41 Injection is not available. 
42 Available dose is 5mg/1ml iv or im injection 
43 Available dose is 5mg/1ml are intended for various other reasons not for PTRDS. PTRDS needs 6mg im/iv dose that is not available. SDGs are being prepared. 
44 Available but not in appropriate dose form. Not in injection form. 
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Name of 
commodity 
Regis
tered
? 
Indication? Available dose? 
Presentati
on? 
Listed in 
EDL? 
What is the policy? 
Service 
delivery 
guidelin
es exist? 
Availability 
Storing place? 
Who can 
administer? 
Procure
ment? 
Able to 
forecast 
supply needs? 
In 
country 
manufac
turing? 
Qualit
y 
assura
nce 
guideli
nes 
exist? 
Qualit
y 
contro
l lab 
exists? 
Stakeholder 
interest in roll 
out UN 
recommendati
on? 
Government facility? 
Private/Drug 
Store? 
Natio
nal 
Distric
t 
Subdi
strict 
Commu
nity 
Nati
onal 
Commu
nity 
Public Private 
Natio
nal 
Subna
tional 
C
h
lo
rh
e
x
id
in
e
  
digluconate  No 
- Neonatal 
umbilical 
cord care 
7.1% not 
available 
- No 
-recently approved 
for newborn cord 
care at facility and 
community  
-single use during 
umbilical cord 
stamp followed by 
dry cord care 
No45 No No No No No No - - 
Trained 
service 
providers 
- Yes No Planned - Yes39 Interested 
gluconate Yes46 
Vaginal 
cleansing 
0.16% – 0.60% Solution 
Yes 
- reduce bacterial 
infection in various 
situation 
-over the counter 
Yes Yes Yes Yes Yes Yes Yes Shelf Shelf 
Trained 
service 
providers 
Centrali
zed37 
Yes No Yes Yes Yes39 - 
Neonatal 
skin wiping 
0.16% – 0.60% 
Solution, 
Hand rub 
Eyewash .05% Solution 
Dental wash 0.12%-1% Solu,, gel 
Preoper. 
skin 
cleansing 
2.0% Solution 
Resuscitation 
devices 
Yes 
- Newborn 
asphyxia 
240 ml/500 ml 
size volume, 
specifically 
designed 
Self-
inflating 
bag, mask 
& suction 
devices 
No 
-manage newborn 
asphyxia 
Yes Yes Yes47 Yes47 No47 Yes No Shelf Shelf 
Trained 
service 
providers 
Donated Yes No No No No Interested 
ORS48 Yes - Diarrhea 
Nacl 1.30 gm; 
Kcl 0.75 gm; 
Tri Sodium 
Citrate, Dye 
Hydrate 1.45 
gm; Glucose, 
Anhydrous 
6.75 gm49 
Sachet Yes 
-rehydration 
therapy for 
diarrhea 
- over the counter 
Yes Yes Yes Yes Yes Yes Yes Shelf Shelf 
Over the 
counter 
product 
 
 
 
 
 
Centrali
zed37 
Yes No Yes Yes38 Yes39 
Already in 
system 
Zinc50 Yes - Diarrhea 
Zinc sulphate 
monohydrate 
10 mg/20 mg/5 
ml/tab/syrup 
Tablet  
Yes 
-prevent diarrhea 
-feed for 10 days 
- over the counter 
Yes Yes Yes Yes Yes Yes Yes Shelf Shelf 
Over the 
counter 
product 
Centrali
zed37 
Yes No Yes Yes38 Yes39 
Already in 
system 
Syrup 
Female condom No - - - - Not interested  - - - - - - - - - - - - - - - - 
Contraceptive 
implants 
(implanon/ Jadelle) 
Yes 
-long-term 
(3-5 yrs) 
female 
contraceptio
n  
68 mg 
etonogestrel  
One rod In the 
method 
mix 
-On-demand 
-Available at 
designated facility 
-any woman eligible 
even nulliparous 
Yes Yes Yes Yes No51 No52 No Shelf Shelf 
Only trained 
Physician 
Centrali
zed 
Yes No No No No 
Already in 
system 75 mg 
levonorgestrel 
Two rods 
Emergency 
contraception 
Yes 
-Back-up 
contraceptio
n 
0.75 mg/ 1.5 
mg/tab 
Levonorgestrel 
Tablet 
DGFP 
method 
mix 
- over the counter 
-single dose within 
5 days of 
unprotected sex 
Yes Yes Yes53 Yes53 Yes53 Yes Yes Shelf Shelf 
Over the 
counter 
product 
Centrali
zed 
Yes No Yes Yes38 Yes39 
Already in 
system 
                                                                        
 
45 One piloting is being conducted and working with MOH for the preparation and guidelines for the required concentration (7.1% chlorhexidine digluconate for cord cleansing). 
46 The ingredient is registered but the concentration required for newborn cord care is not available or registered. Various concentration and combination is available. They are all Chlorhexidine gluconate and hydrochloride not Chlorhexidine digluconate. 
47 Only in district where HBB program was implemented. In most of the places it is not available. 
48 Also available with supplements 
49 WHO & UNICEF new formulae for ORS 
50 Also available with supplements 
51 In most places not available but in some places available where primary level facilities are upgraded or camps are being organized. 
52 In a very few places it available with NGO initiatives. 
53 Policy is there to make it available but there is lack of supply. 
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Table 3b: Availability matrix of 13 life-saving maternal and neonatal health commodities in Bangladesh, by pharmaceutical companies,  
market retail price, available packaging, and willingness to pay by end users 
Name of commodity Name of pharmaceutical companies who manufacture it Brand names Available dose? Market prices? 
Separate 
packaging? 
WTP by 
end-user? 
Oxytocin 
Nuvista Phar. Ltd., Opsonin Phar. Ltd., Chemist Laboratories Ltd., Techno 
Drugs 
Linda-S, Ocin, Pitocin, Syntocin 5 iu/1ml ampule Tk.54 8-11/amp No Yes55 
Misoprostol56 Incepta Phar. Ltd., Gonoshasthaya Phar. Ltd., Square Phar. Ltd. Cytomis,  G-Misoprostol, Isovent 
100 mcg Tk..8/tab 
Yes57 Yes55 
200 mcg Tk.10-15/tab 
Magnesium Sulphate heptahydrate BP 
(MgSO4) 
Opsonin Phar. Ltd, Gonoshasthaya Phar. Ltd (GPL), Renata Ltd, Gonoshasthaya Phar. 
Ltd (GPL), Beximco Phar. Ltd. 
Eclamsil 49.3%, G-Magsulph 49.3%, 
Magsum 49.3% 
49.3% w/v in 5ml amp (2.46 
gm) 
Tk. 20-25/5ml amp 
No Yes55 
G-Magsulph 4%, Nalepsin 4% 4% w/v in 100 ml iv. solution 
Tk. 55-71/100 ml 
bot. 
Injectable antibiotics 
ACME Laboratories Ltd, Renata Ltd 
Combipen 4 Lac, Pronapen 4 Lac 
(Procaine penicillin 3 lac -f 
Benzyl penicillin 1 lac/vial) 
(1g =1 million IU) 
(50 mg/kg IM) 
Tk. 6-10/vial 
No Yes55 
In
je
c
ta
b
le
 a
n
ti
b
io
ti
c
s 
Procaine benzyl penicillin 
Pronapen 8 Lac 
Procaine penicillin 6 lac, 
Benzyl penicillin 2 lac (total 8 
lac) in 1 vial 
Tk. 10/vial 
Gentamicin 
sulphate 
Edruc Ltd, Square Phar. Ltd., Square Phar. Ltd., Popular Phar. Ltd., Techno Drugs, 
Opsonin Phar. Ltd, GPL, Incepta Phar. Ltd., Beximco Phar. Ltd., Aristopharma Ltd. 
Egen, Genacyn, Genacyn, Gentabac, 
Gentasol, Gentin, G-Gentamicin, 
Intamycin, Invigen 
20 mg Tk. 6-7/2 ml amp 
No Yes55 
80 mg 
Tk. 9.50-12/2 ml 
amp 
80 mg iv infusion Tk. 48/100 ml vial   
Ceftriaxone 
Renata Ltd., Techno Drugs, IBN SINA Phar. Industry Ltd., Aristopharma Ltd., Beximco 
Phar. Ltd., ACI Ltd, Novo Healthcare and Phar. Ltd., Square Phar. Ltd., Drug 
International Ltd., Sanofi-aventis (Bd) Ltd., Popular Phar. Ltd., Incepta Phar. Ltd., GPL, 
General Phar. Ltd., Rephco Laboratories Ltd., Apex Phar. Ltd., Sandoz/Novartis (Bd) 
Ltd., Healthcare Phar. Ltd, Rangs Phar. Ltd., Jayson Phar. Ltd., Kemiko Phar. Ltd., 
Radiant Phar. Ltd., Navana Phar. Ltd., Medimet Phar. Ltd., Opsonin Phar. Ltd, Globe 
Phar. Ltd., Eskayef (Bd) Ltd., Ziska Phar. Ltd., ACME Laboratories Ltd., Orion Phar. 
Ltd., Bio-pharma Laboratories Ltd., Libra Phar. Ltd. 
Ceftizone, Cefixon, Axosin, Axon, Arixon, 
Aciphin, Ceftrix, Ceftron, Dicephin, 
Enocef, Eracef, Exephin, G-Ceftriax, 
Imacef, Inoxon, Keptrk, Megion, Oricef, 
Oryx, Parcef, Rit, Rofecin, Topcef, Trax, 
Traxon, Tribac, Triject, Triphin, Trizon, 
Vertex, Winner, Xylib 
250 mg iv/im Tk. 75-130/vial 
No Yes55 
500 mg iv/im Tk. 120-145/vial 
1 gm iv/im Tk. 160-195/vial 
2 gm iv/im Tk. 250-350/vial 
im injections are almost same. In some cases it is 
Tk. 20-25 less 
A
m
o
x
ic
il
li
n
 
Amoxicillin 
Square Phar. Ltd. Moxacil DT 
 
250 mg/DT 
 
Tk. 3.50/DT tab. 
Yes Yes 
Dispersible tablet (DT) 
Injection 
Opsonin Phar. Ltd, Renata Ltd., Jayson Phar. Ltd., ACI Ltd., Drug International Ltd., 
Gonoshasthya Phar. Ltd., Square Phar. Ltd., Acme Laboratories Ltd., Techno Drugs, 
Gaco Phar. Ltd. 
Amoxi, Amoxon, Avlomox, Demoxil, G-
Amoxycillin, Moxaci, Moxilin, Moxin, 
Penmox, Unimox 
250 mg/vial (iv/im) Tk. 18-22/vial 
500 mg/vial (iv/im) Tk. 21-27/vial 
1000 mg/vial (iv/im) Tk. 46/vial 
Drop 
Aexim Phar. Ltd., Ambee Phar. Ltd., Sonear Laboratories Ltd., Syntho Laboratories 
Ltd., Pacific Phar. Ltd., Bio Phar. Laboratories Ltd., Doctor’s Chemicals Works Ltd., 
Renata Ltd., Cosmo Phar. Laboratories Ltd., Medicon Laboratories Ltd., Glaxo Smith 
Kline (Bd) Ltd, Modern Phar. Ltd., Salton Phar. Ltd., Zenith Phar. Ltd., Jayson Phar. 
Ltd., Rangs Phar. Ltd., Apollo Phar. Laboratories Ltd., Apex Phar. Ltd , Aristopharma 
Ltd., ACI Ltd., Benham Phar. Ltd., Bristol Phar. Ltd., Cosmic Chemical Industries Ltd., 
Kumudini Phar. Ltd., Desh Phar. Ltd., Drug International Ltd., Hallmark Phar. Ltd., 
Elixir Phar. Ltd., Edruc Ltd., Popular Phar. Ltd., Sanofi-Aventis (Bd) Ltd., GPL, General 
Phar. Ltd., Millat Phar. Ltd., Medimet Phar. Ltd., Hudson Phar. Ltd., Ad-din Phar. Ltd., 
Kemiko Phar. Ltd., Asiatic Laboratories Ltd., Belsen Phar. Ltd., Amico Laboratories 
Ltd., Central Phar. Ltd., Proteety Phar. Ltd., Decent Phar. Ltd., Square Phar. Ltd., Nipa 
Phar. Ltd., Marksman Phar. Ltd., Supreme Phar. Ltd., Acme Laboratories Ltd., Opsonin 
Phar. Ltd, Shamsul Alamin Phar. Ltd., Mystic Phar. Ltd., Navana Phar. Ltd., Orion 
Laboratories Ltd., Peoples Phar. Ltd., Globex Phar. Ltd., APC Phar. Ltd., Techno 
Drugs, Pharmadesh Laboratories Ltd., Reman Drug Laboratories Ltd., Rasa Phar. Ltd., 
Rephco Laboratories Ltd., Alco Phar. Ltd., Seema Phar. Ltd., Silva Phar. Ltd., Ibn Sina 
Almoxil, Ambeexin, Amocap, Amocil, 
Amocin, Amotid, Amotid, Amox, Amoxi, 
Amoxic, Amoxicap, Amoxicon, Amoxil, 
Amoxima, Amoxipan, Amoxizen, 
Amoxon, Antif, Apimox, Apoxy, 
Aristomox, Avlomox, Bactamox, Benoxil, 
Bpmox, Brodamox, Clamox, Demox, 
Demoxil, Dopen, Elimox, E-Mox, Fimox, 
Fimoxyl, G-Amoxycillin, Genamox, 
Hectamox, Hiconcil, Hi-Mox, J-Mox, 
Kamoxy, Loxyl, Moci, Monamox, 
Cemoxin, Mox, Moxa, Moxacil, Moxapen, 
Moxatid, Moxico, Moxilin, Moxin ,Mox, 
Mumox, Mymoxcil, Navamox, Orixyl, 
Pamoxil, Panoxyl, Pemox, Penmox, 
Pharmoxyl, Remamox, Roxyl, Remoxin, 
100 mg/1ml 
 
Tk. 27-31/15 ml bot. 
Yes Yes55 
125 mg/1.25 ml Tk. 27-31/15 ml bot. 
Suspension 
125 mg/5ml 
Tk. 40-55/100 ml 
bot. 
250 mg/5ml 
Tk. 60-68/100 ml 
bot. 
Capsule 
250 mg/cap Tk. 2.50-3.50/cap 
500 mg/cap Tk. 4.50-6.50/cap 
Tablet 
250 mg/tab Tk. 3.5-4.0/tab 
875 mg/tablet Tk. 8.50-10.00/tab 
                                                                        
 
54 1 US$=80 Taka or 1 taka=US$ 0.013 
55 If not available in the government system people purchase. But needs “safety net”. 
56 Pharmaceuticals branded it as anti-ulcerant, in combination with anti-inflammatory drugs, in combination with mifepristone for medial MR 
57 Also for medical termination of pregnancy in combination with mifepristone. 
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Name of commodity Name of pharmaceutical companies who manufacture it Brand names Available dose? Market prices? 
Separate 
packaging? 
WTP by 
end-user? 
Phar. Ind. Ltd., Eskayef (Bd) Ltd., Skylab Ltd., Beximco Phar. Ltd., Somatec Phar. Ltd., 
Globe Phar. Ltd., Gaco Phar. Ltd., Ziska Phar. Ltd. 
Sapox, Seemaxyl, Simox, Sinamox, Sk-Mox 
, Skymoxin, Tycil, Tymox, Ultramox, 
Unimox, Zimoxyl 
A
n
te
n
a
ta
l 
c
o
rt
ic
o
st
e
r
o
id
s 
(A
N
C
S
) 
Dexamethasone sodium phosphate 
Could manufacture by all pharmaceuticals below - 
5 mg/1ml amp but 6 mg/12 
mg/1ml amp not available58 
- - - 
Globe Phar. Ltd., Techno Drugs, Opsonin Phar. Ltd, Renata Ltd., Medimet Phar. Ltd., 
Rephco Laboratories Ltd., Globe Phar. Ltd., Techno Drugs, Renata Ltd., Medimet 
Phar. Ltd., Rephco Laboratories Ltd., Jayson Phar. Ltd., Chemist Laboratories Ltd., Ibn 
Sina Phar. Industries Ltd., Ziska Phar. Ltd., Gonoshasthya Phar. Ltd., Gaco Phar. Ltd., 
Nuvista Phar. Ltd., Aristopharma Ltd. 
D-Cort, Decafos, Decason, Dexa, Dexam, 
Dexamet, D-Cort, Decafos, Decason, 
Dexa, Dexam, Dexamet, Dexamin, Dexan, 
Dexon, Dextason, G-Dexamethasone, 
Meradexon, Oradexon, Sonexa 
5 mg/1 ml amp Tk. 9-22/amp No Yes55 
Betamethasone59 sodium phosphate Manufacture by a number of pharmaceuticals but different preparation no injection - 
Ointment, drop, cream, tablet 
(Glaxo) 
- No - 
C
h
lo
rh
e
x
id
in
e
 
Digluconate Not manufacture by any pharmaceuticals - 7.1% aqueous solution - No Yes55 
G
lu
c
o
n
a
te
 
Solution 
Gonoshasthaya Phar. Ltd, Square Phar. Ltd., Eskayef Bangladesh Ltd., ACI Ltd, 
Opsonin Phar. Ltd, Silva Phar. Ltd, Silva Phar. Ltd, Medimet Phar. Ltd., Aristopharma 
Ltd. 
G-Antiseptic, Germisol, Handirub, 
Hexiscrub, Hexisol, Kevirub, Safetisol, 
Safetisol, Safwash, Xisol, Oralon, Oralon 
Dental 
 
BP solution 
Tk. 16-31/100 ml 
bot. 
No Yes55 
Hand Rub 
Chlorhexidine gluconate 0.5% 
w/w in 70% Isopropanol 
solutions 
Tk. 24-31/50 ml bot. 
Tk. 80-105/250 ml 
bot. 
Hand Rub 
Chlorhexidine gluconate 0.5% 
w/v in Isopropyl alcohol 20% 
w/v solution 
Tk. 30/50 ml bot Tk. 
80/200 ml bot 
Solution (Mouth Wash) 0.2% w/v solution Tk. 35/100 ml bot. 
Solution 4% solution Tk. 100/250 ml bot. 
Resuscitation devices NA - 
240 ml/500 ml size volume, 
specifically designed 
NA Not needed No 
ORS60 SMC ORSaline-N, ORS Fruti, Tasti saline 
Sodium Chloride 1.30 gm; 
Potassium Chloride 0.75 gm; 
Tri Sodium Citrate, Dye 
Hydrate 1.45 gm; Glucose, 
Anhydrous 6.75 gm61 
Tk. 4.5-6.0/pack Not needed Yes55 
Zinc62 
Sulphate monohydrate 
Acme Laboratories Ltd., Pacific Phar. Ltd., Bristol Phar. Ltd., Benham Phar. Ltd., CPL, 
ACI Ltd., Elixir Phar. Ltd., Eskayef Bangladesh Ltd., Edruc Ltd, GPL, Ibn Sina Ltd., Ad-
din Phar. Ltd., Gaco Phar., Renata Ltd, Opsonin Phar. Ltd, NOVO Healthcare and 
Phar. Ltd., Aristopharma Ltd., Navana Phar. Ltd., Supreme Phar, Proteety Phar. Ltd., 
Orion Phar. Ltd., Nipa Phar. Ltd., Rasa Phar. Ltd., Popular Phar. Ltd., Pharmadesh 
Laboratories Ltd., Pharmacia Pvt. Ltd., Jayson Phar. Ltd., Beximco Phar. Ltd., Hudson 
Phar. Ltd., Chemist Laboratories Ltd., Cosmic Phar. Pvt Ltd., Alco Phar. Ltd., Square 
Phar. Ltd., General Phar. Ltd., Incepta Phar. Ltd., Globe Phar. Ltd., Zenith Phar. Ltd, 
Apollo Phar. Laboratories Ltd., Desh Phar. (Pvt.) Ltd., Somatec Phar. Ltd., Ziska Phar. 
Ltd., Ambee Phar. Ltd., Bikalpa Phar. Ltd., Bio Phar. Laboratories Ltd., Modern Phar. 
Ltd., Medicon Laboratories Ltd., Kumudini Phar. Ltd., Rephco Laboratories Ltd., Apex 
Phar. Ltd., Acme Laboratories Ltd., Chemico Laboratories Ltd., Marksman Phar. Ltd., 
Medimet Phar. Ltd, Drug International Ltd., Unimed & Unihealth Manufacturers Ltd., 
Delta Phar. Ltd, Decent Phar. Laboratories Ltd., Silva Phar. Ltd., Hallmark Phar. Ltd., 
Baby Zinc, Bimuty, Bimuty, Bp Zinc, B-Zn, 
C-Zinc, Dispazinc, E-Zinc, Ezy Xinc, 
Grow, G-Zinc, Inate, J-Zinc, Kids-B, Mazic, 
Nid, Novo Zinc, Oral-Z, Oralzin, Orazinc, 
Pedi-Z, Pem Ds, Pep-2, Peptin, Rozinc, 
Soluzinc, Syrup Zinc, Syrup-Zp, Tiny-Z, 
Xinc, Z-Dt, Zeal, Zedex, Zee-2, Zeenee, 
Zeenk, Zep, Zesup, Zico, Zido, Ziflu, 
Zikid, Zimon, Zinca, Zincep, Zincol, 
Zincoral, Zinc-S, Zincsy, Zinga, Zinofa, 
Zinon, Zinpro, Zinup, Zipol, Zis Ds, 
Zismo, Zisul, Zisulmet, Ziton, Zixol, 
Znkid, Zs, Z-Sil Dt, Z-Sil, Zym 
20 mg/tab 
 
Tk. 1.5-2.0/20 mg 
tab 
Not needed Yes55 
10 mg/5ml syrup 
 
Tk. 25-30/100 ml 
bot. 
20 mg/5ml syrup 
Tk. 50-55/100 ml 
bot. 
Female condom Not available - - - - - 
Contraceptive implants 
(Implanon/Jadelle) 
Implanon imported from Organon. Marketed by MSD and local distributor is Janata 
Traders 
Implanon 68 mg etonogestrel/rod $ 8.5-10/implant 
Yes No 
Jadelle imported from Bayer Schering Phar. AG (I-plant) 75 mg levonorgestrel/rod $ 8.0-10/two stick 
Emergency contraception 
Imported from Gedeon Richter (City Overseas), and Renata Ltd., SMC, 
Square Phama. Ld. 
Postinor-2, Emcon, Norix, Norpil 1 
0.75 mg/1.5 mg of 
Levonorgestrel/tab 
Tk. 30-45/two tab Yes Yes55 
 
                                                                        
 
58 Available dose is 5mg/1ml iv or im injection 
59 Injection is not available. 
60 Also available with supplements 
61 WHO & UNICEF new formulae for ORS 
62 Also available with supplements such as vitamins 
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 Appendix 1: Bangladesh Essential Drugs List 
 LIST OF ESSENTIAL DRUGS 
 Sl.  Name of drugs  Dosage form  
1  Abacavir (ABC)  Oral Liquid, Tablet  
2  Acetazolamide  Tablet  
3  Acetylsalicylic acid  Suppository, Tablet  
4  Aciclovir  Powder for injection, Tablet  
5  Albendazole  Tablet (chewable)  
6  Allopurinol  Tablet  
7  Aluminium hydroxide + Magnesium hydroxide  Oral liquid, Tablet  
8  Amitriptyline  Tablet  
9  Amlodipine Besylate  Tablet  
10  Amoxicillin  Capsule or Tablet, Powder for oral liquid, Powder for 
injection  
11  Ampicillin  Powder for Injection  
12  Anti-D immunoglobulin (human)  Injection  
13  Antitetanus immunoglobulin (human)  Injection  
14  Artemether + Lumefantrine*  Tablet  
15  Artesunate  Injection, Tablet  
16  Ascorbic Acid  Tablet  
17  Atenolol  Tablet  
18  Atropine  Injection, Solution (eye drops)  
19  Barium Sulfate  Aqueous suspension  
20  BCG vaccine  Injection  
21  Benzathine benzylpenicillin  Powder for injection  
22  Benzoic acid + Salicylic acid  Ointment or cream  
23  Benzyl benzoate  Lotion  
24  Benzyl penicillin  Powder for injection  
25  Betamethasone  Ointment or cream  
26  Bleomycin  Powder for injection  
27  Bupivacaine  Injection  
28  Calcium gluconate  Injection  
29  Carbamazepine  Oral liquid, Tablet (chewable), Tablet (scored)  
30  Charcoal, activated  Powder  
31  Chlorambucil  Tablet  
32  Chloramphenicol  Eye drops, Eye ointment  
33  Chlorhexidine  Solution  
34  Chloroquine  Oral liquid, Tablet  
35  Chlorpheniramine  Injection , Tablet  
36  Chlorpromazine  Injection, Oral liquid, Tablet  
37  Ciprofloxacin  Tablet or powder for suspension  
38  Cisplatin  Injection  
39  Clofazimine  Capsule  
40  Clotrimazole  Vaginal cream, Vaginal tablet  
41  Cloxacillin  Capsule, Powder for injection, Power for oral liquid,  
42  Condoms   
43  Cyclophosphamide  Powder for injection, Tablet  
44  Dapsone  Tablet  
45  Dexamethasone  Injection  
46  Dextran 70  Injectable solution  
47  Diazepam  Injection, Tablet, Tablet (scored)  
48  Didanosine (ddl)  Buffered powder for oral liquid, Capsule (unbuffered enteric 
coated), Tablet (buffered chewable, dispersible)  
49  Diethylcarbamazine  Tablet  
50  Digoxin  Injection, Oral liquid, Tablet  
51  Diloxanide  Tablet  
52  Diphtheria antitoxin  Injection  
53  Diptheria vaccine  Injection  
54  Dopamine  Injection  
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55  Doxorubicin  Powder for injection  
56  Doxycycline  Capsule or Tablet, Tablet (dispersible)  
57  DPT vaccine  Oral + Injection  
58  Efavirenz (EFV or EFZ)  Capsule, Oral liquid, Tablet  
59  Enalapril  Tablet  
60  Epinephrine (adrenaline)  Injection, Solution (eye drops)  
61  Ergocalciferol  Capsule or Tablet, Oral liquid  
62  Ergometrine  Injection  
63  Erythromycin  Capsule or Tablet, Powder for injection, Powder for oral 
liquid  
64  Ethambutol  Tablet  
65  Ethinylestradiol + Levonorgestrel  Tablet  
66  Ferrous salt  Oral liquid, Tablet  
67  Ferrous salt + Folic acid  Capsule, Tablet  
68  Fluconazole  Capsule, Oral liquid  
69  Fluorescein  Eye drops  
70  Fluorouracil  Injection, Ointment  
71  Fluphenazine  Injection  
72  Folic acid  Tablet  
73  Furosemide  Injection, Tablet  
74  Gentamycin  Injection, Solution (eye drops)  
75  Gentamycin + Hydrocortisone  Ear drop  
76  Glibenclamide  Tablet  
77  Gliclazide  Tablet  
78  Glucose  Injectable solution  
79  Glucose with sodium chloride  Injectable solution  
80  Glyceryl trinitrate  Tablet (sublingual)  
81  Griseofulvin  Capsule or Tablet  
82  Haloperidol  Injection, Tablet  
83  Halothane  Inhalation  
84  Heparin sodium  Injection  
85  Hepatitis B vaccine  Injection  
86  Homatropine  Solution (eye drops)  
87  Human normal immunoglobulin  Intramuscular administration, Intravenous administration  
88  Hydrochlorothiazide  Tablet (scored)  
89  Hydrocortisone  Powder for injection, Ointment or cream, Suppository  
90  Hyoscine butylbromide  Tablet, Injection  
91  Ibuprofen  Tablet  
92  Indinavir (IDV)  Capsule  
93  Insulin Injection (Soluble)  Injection  
94  Isoniazide  Tablet, Tablet (scored)  
95  Isoniazide + Ethambutol  Tablet  
96  Isosorbide dinitrate  Tablet (sublingual)  
97  Ketamine  Injection  
98  Lamivudine (3TC)  Oral liquid, Tablet,  
99  Levamisole  Tablet  
100  Levodopa + Carbidopa  Tablet  
101  Levothyroxine  Tablet  
102  Lidocaine  Injection, Topical  
103  Lithium Carbonate  Capsule or tablet  
104  Lopinavir + Ritonavir (LPV/r)  Capsule, Oral liquid  
105  Magnesium hydroxide  Oral liquid  
106  Magnesium sulfate*  Injection  
107  Mannitol  Injectable solution  
108  Measles vaccine  Injection  
109  Mebendazole  Tablet (chewable)  
110  Mefloquine  Tablet  
111  Metformin  Tablet  
112  Methotrexate  Powder for injection, Tablet  
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113  Methyldopa  Tablet : 250 mg  
114  Methylrosanilinium chloride (gentian violet)  Aqueous solution, Tincture  
115  Metoclopramide  Injection, Tablet  
116  Metronidazole  Injection, Oral liquid, Suppository, Tablet  
117  Miconazole  Ointment/Ceam  
118  Miltefosine  Capsule/Oral liquid  
119  Misoprostol  Tablet  
120  Morphine  Injection, Oral liquid, Tablet, Tablet (prolonged release)  
121  Naloxone  Injection  
122  Nelfinavir (NFV)  Oral powder, Tablet  
123  Neomycin Sulfate + Bacitracin  Ointment  
124  Neostigmine  Injection, Tablet  
125  Nevirapine (NVP)  Oral liquid, Tablet  
126  Nicotinamide  Tablet  
127  Nifedipine  Immediate release capsule  
128  Nitrofurantoin  Tablet  
129  Nitrous oxide  Inhalation  
130  Nystatin  Oral Suspension  
131  Omeprazole  Capsule  
132  Oral rehydration salts  Powder  
133  Oseltamivir  Tablet  
134  Oxygen  Inhalation  
135  Oxytocin  Injection  
136  Paracetamol  Oral liquid, Suppository, Tablet  
137  Paromomycin  Solution for intramuscular injection  
138  Peritoneal Dialysis Solution  Intraperitoneal dialysis solution (of appropriate composition)  
139  Permethrin  Cream, Lotion  
140  Pertussis vaccine  Injection  
141  Pethidine hydrochloride  Injection  
142  Phenobarbital  Injection, Oral liquid, Tablet  
143  Phenoxymethylpenicillin  Powder for oral liquid, Tablet,  
144  Phenytoin  Capsule, Injection, Oral liquid, Tablet, Tablet (chewable)  
145  Pilocarpine  Solution (eye drops)  
146  Poliomyelitis vaccine  Oral  
147  Polyvalent anti snake venom  Injection  
148  Potassium chloride  Tablet, Solution  
149  Povidone Iodine  Solution  
150  Prednisolone  Tablet, Solution (eye drops)  
151  Primaquine  Tablet  
152  Procainamide  Injection  
153  Procaine benzylpenicllin  Powder for injection  
154  Procarbazine  Capsule  
155  Proguanil  Tablet  
156  Promethazine  Oral liquid, Injection, Oral liquid, Tablet  
157  Propranolol  Tablet  
158  Protamine sulfate  Injection  
159  Pyrazinamide  Tablet, Tablet (dispersible), Tablet (scored)  
160  Pyridoxine  Tablet  
161  Pyrimethamine  Tablet  
162  Quinine  Injection, Tablet  
163  Rabies immunoglobulin  Injection  
164  Rabies vaccine  Injection  
165  Retinol  Capsule, Tablet, Oral oily solution, Water-miscible injection  
166  Riboflavin  Tablet  
167  Rifampicin  Capsule or Tablet  
168  Rifampicin + Isoniazid  Tablet  
169  Rifampicin + Isoniazid + Ethambutol  Tablet  
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170  Rifampicin + Isoniazid + Pyrazinamide  Tablet  
171  Rifampicin + Isoniazid + Pyrazinamide + Ethambutol  Tablet  
172  Ritonavir  Oral liquid, Oral solid dosage form  
173  Salbutamol  Injection, Oral liquid, Respirator solution for use in nebulizers, 
Tablet  
174  Salicylic acid  Solution  
175  Saquinavir (SQV)  Capsule  
176  Senna  Tablet  
177  Silver sulfadiazine  Cream  
178  Sodium chloride  Injectable solution  
179  Sodium Chloride 3%  I/V fluid  
180  Sodium Chloride quartet strength (0.225%) + 
Dextrose 5%  
I/V fluid  
181  Sodium Hydrogen Carbonate  Injectable solution, Soution  
182  Sodium stibogluconate  Injection  
183  Sodium thiosulfate  Solution  
184  Spironolactone  Tablet  
185  Stavudine (d4t)  Capsule, Powder for oral liquid  
186  Streptomycin  Powder for injection  
187  Sulfadoxine + Pyrimethamine  Tablet  
188  Sulfamethoxazole + Trimethoprim  Oral liquid, Tablet, Injection  
189  Suxamethonium  Injection, Powder for injection  
190  Tamoxifen  Tablet  
191  Tenofovir disoproxil fumarate (TDF)  Tablet  
192  Tetanus vaccine  Injection  
193  Tetracycline  Eye ointment  
194  Thiamine  Tablet  
195  Thiopental  Powder for injection  
196  Trimethoprim  Tablet  
197  Tropicamide  Eye drops  
198  Tuberculin, purified protein derivative (PPD)  Injection  
199  Valproic acid  Oral liquid, Tablet (crushable), Tablet (enteric coated)  
200  Vecuronium  Injection  
201  Verapamil  Injection, Tablet  
202  Vinblastine  Powder for injection  
203  Vincristine  Powder for injection  
204  Vitamin B-Complex (Vitamin B1- 5 mg + Vitamin B2- 
2 mg + Vitamin B6 - 2 mg + Nicotinamide 20 mg)  
Tablet  
205  Warfarin  Tablet  
206  Water for Injection  Ampoule  
207  Xylometazoline Hydrochloride  Nasal drops  
208  Zidovudine (ZDV or AZT)  Capsule, Oral liquid, Solution for IV infusion injection, Tablet  
209  Zinc sulphate  Oral liquid, Tablet  
N.B: Shaded items are the drugs in the 13 life-saving commodities 
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